Publications

Publications 2024

Arffman M, Meriranta L, Autio M, Holte H, Jørgensen J, Brown P, Jyrkkiö S, Jerkeman M, Drott K, Fluge Ø, Björkholm M, Karjalainen-Lindsberg ML, Beiske K, Pedersen MØ, Leivonen SK, Leppä S (2024)
Inflammatory and subtype-dependent serum protein signatures predict survival beyond the ctDNA in aggressive B cell lymphomas
Med (in press)
DOI 10.1016/j.medj.2024.03.007, PubMed 38579729

Gomes LA, Rodrigues AM, van der Windt D, Pires D, Afreixo V, Canhão H, Cruz EB (2024)
Minimal Intervention of Patient Education for Low Back Pain: A Systematic Review With Meta-analysis
J Orthop Sports Phys Ther, 54 (2), 1-13
DOI 10.2519/jospt.2023.11865, PubMed 37970797

Pulczynski EJ, Simonsen MR, Kuittinen O, Fagerli UM, Erlanson M, Fluge Ø, Leppä S, Østenstad B, Fosså A, Eriksson M, El-Galaly T, Kuitunen H, Papworth K, Ljungqvist M, Pedersen MB, Pollari M (2024)
Elderly long-term survivors in the Nordic phase II study with first-line maintenance temozolomide for primary central nervous system lymphoma: a 10-year follow-up
Haematologica (in press)
DOI 10.3324/haematol.2024.285207, PubMed 38546689

Rask Kragh Jørgensen R, Bergström F, Eloranta S, Tang Severinsen M, Bjøro Smeland K, Fosså A, Haaber Christensen J, Hutchings M, Bo Dahl-Sørensen R, Kamper P, Glimelius I, E Smedby K, K Parsons S, Mae Rodday A, J Maurer M, M Evens A, C El-Galaly T, Hjort Jakobsen L (2024)
Machine Learning-Based Survival Prediction Models for Progression-Free and Overall Survival in Advanced-Stage Hodgkin Lymphoma
JCO Clin Cancer Inform, 8, e2300255
DOI 10.1200/CCI.23.00255, PubMed 38608215

Stoevesandt D, Ludwig C, Mauz-Körholz C, Körholz D, Hasenclever D, McCarten K, Flerlage JE, Kurch L, Wohlgemuth WA, Landman-Parker J, Wallace WH, Fosså A, Vordermark D, Karlén J, Cepelová M, Klekawka T, Attarbaschi A, Hraskova A, Uyttebroeck A, Beishuizen A, Dieckmann K, Leblanc T, Daw S, Steglich J (2024)
Pulmonary lesions in early response assessment in pediatric Hodgkin lymphoma: prevalence and possible implications for initial staging
Pediatr Radiol (in press)
DOI 10.1007/s00247-024-05859-y, PubMed 38296856

Publications 2023

Ask EH, Tschan-Plessl A, Hoel HJ, Kolstad A, Holte H, Malmberg KJ (2023)
MetaGate: Interactive Analysis of High-Dimensional Cytometry Data with Meta Data Integration
bioRxiv
DOI 10.1101/2023.10.27.564454, PubMed 37961421

Dahl AA, Smeland KB, Eikeland S, Fagerli UM, Bersvendsen HS, Fosså A, Kiserud CE (2023)
Work ability and work status changes in long-term Hodgkin lymphoma survivors with focus on late adverse effects
J Cancer Surviv (in press)
DOI 10.1007/s11764-023-01432-y, PubMed 37526861

Eikeland SA, Smeland KB, Simensen VC, Fagerli UM, Bersvendsen HS, Kiserud CE, Fosså A (2023)
Chronic fatigue in long-term survivors of Hodgkin's lymphoma after contemporary risk-adapted treatment
Acta Oncol, 62 (1), 80-88
DOI 10.1080/0284186X.2023.2168215, PubMed 36715320

Entrop JP, Weibull CE, Smedby KE, Jakobsen LH, Øvlisen AK, Glimelius I, Marklund A, Larsen TS, Holte H, Fosså A, Smeland KB, El-Galaly TC, Eloranta S (2023)
Reproduction patterns among non-Hodgkin lymphoma survivors by subtype in Sweden, Denmark and Norway: A population-based matched cohort study
Br J Haematol, 202 (4), 785-795
DOI 10.1111/bjh.18938, PubMed 37325886

Entrop JP, Weibull CE, Smedby KE, Jakobsen LH, Øvlisen AK, Molin D, Glimelius I, Marklund A, Holte H, Fosså A, Smeland KB, El-Galaly TC, Eloranta S (2023)
Reproduction patterns among classical Hodgkin lymphoma survivors treated with BEACOPP and ABVD in Sweden, Denmark and Norway-A population-based matched cohort study
Int J Cancer, 153 (4), 723-731
DOI 10.1002/ijc.34552, PubMed 37119033

Flølo TN, Fosså A, Nedkvitne JIP, Waage JER, Rekdal M, Dankel SN, Fernø J, Mellgren G, Nedrebø BG (2023)
Long-term impact of gastropexy on use of acid-reducing medication, second operations for gastroesophageal reflux and subjective reflux symptoms after sleeve gastrectomy
Clin Obes, 13 (5), e12618
DOI 10.1111/cob.12618, PubMed 37583310

Foldvari Z, Knetter C, Yang W, Gjerdingen TJ, Bollineni RC, Tran TT, Lund-Johansen F, Kolstad A, Drousch K, Klopfleisch R, Leisegang M, Olweus J (2023)
A systematic safety pipeline for selection of T-cell receptors to enter clinical use
NPJ Vaccines, 8 (1), 126
DOI 10.1038/s41541-023-00713-y, PubMed 37607971

Fosså SD, Haugnes HS, Dahl AA, Kiserud CE, Fosså A, Skalleberg J, Myklebust TÅ (2023)
Adverse health outcomes and global quality of life in long-term testicular cancer survivors: a longitudinal 30-year perspective
Ann Oncol, 34 (12), 1165-1174
DOI 10.1016/j.annonc.2023.09.3101, PubMed 37739265

Franke FC, Damek A, Steglich J, Kurch L, Hasenclever D, Georgi TW, Wohlgemuth WA, Mauz-Körholz C, Körholz D, Kluge R, Landman-Parker J, Wallace WH, Fosså A, Vordermark D, Karlen J, Fernández-Teijeiro A, Cepelova M, Klekawka T, Attarbaschi A, Ceppi F, Hraskova A, Uyttebroeck A, Beishuizen A, Dieckmann K, Leblanc T et al. (2023)
Differentiation between rebound thymic hyperplasia and thymic relapse after chemotherapy in pediatric Hodgkin lymphoma
Pediatr Blood Cancer, 70 (8), e30421
DOI 10.1002/pbc.30421, PubMed 37243889

Gerdtsson AS, Matos Rodrigues J, Eskelund CW, Husby S, Grønbæk K, Räty R, Kolstad A, Geisler C, Porwit A, Jerkeman M, Ek S (2023)
Overexpression of the key metabolic protein CPT1A defines mantle cell lymphoma patients with poor response to standard high-dose chemotherapy independent of MIPI and complement established highrisk factors
Haematologica, 108 (4), 1092-1104
DOI 10.3324/haematol.2022.281420, PubMed 36519324

Gulbrandsen MS, Nøding AS, Smeland KB, Eikeland SA, Kiserud CE, Hjermstad MJ, Fosså A (2023)
Health-related quality of life, depressive symptoms, and chronic fatigue in long-term survivors of Hodgkin lymphoma
Leuk Lymphoma, 64 (6), 1139-1150
DOI 10.1080/10428194.2023.2198053, PubMed 37144290

Isaksen KT, Galleberg R, Mastroianni MA, Rinde M, Rusten LS, Barzenje D, Ramslien F, Fluge O, Slaaen M, Meyer P, Liestol K, Smeland EB, Lingjarde OC, Holte H, Brodtkorb M (2023)
The Geriatric Prognostic Index: a clinical prediction model for survival of older diffuse large B-cell lymphoma patients treated with standard immunochemotherapy
Haematologica, 108 (9), 2454-2466
DOI 10.3324/haematol.2022.282289, PubMed 36861406

Larsen TL, Svalastoga M, Brekke J, Enden T, Frøen H, Garresori H, Jacobsen EM, Paulsen PQ, Porojnicu AC, Ree AH, Torfoss D, Velle EO, Wik HS, Ghanima W, Sandset PM, Dahm AEA (2023)
Arterial events in cancer patients treated with apixaban for venous thrombosis
Thromb Res, 228, 128-133
DOI 10.1016/j.thromres.2023.05.017, PubMed 37327527

Leich E, Brodtkorb M, Schmidt T, Altenbuchinger M, Lingjærde OC, Lockmer S, Holte H, Nedeva T, Grieb T, Sander B, Sundström C, Spang R, Kimby E, Rosenwald A (2023)
Gene expression and copy number profiling of follicular lymphoma biopsies from patients treated with first-line rituximab without chemotherapy
Leuk Lymphoma, 64 (12), 1927-1937
DOI 10.1080/10428194.2023.2240462, PubMed 37683053

Leivonen SK, Friman T, Autio M, Vaittinen S, Jensen AW, D'Amore F, Hamilton-Dutoit SJ, Holte H, Beiske K, Kovanen PE, Räty R, Leppä S (2023)
Characterization and clinical impact of the tumor microenvironment in post-transplant aggressive B-cell lymphomas
Haematologica, 108 (11), 3044-3057
DOI 10.3324/haematol.2023.282831, PubMed 37259566

Lia K, Jørgensen RRK, L Wold B, Fluge Ø, Fagerli UM, Bersvendsen H, Bø IB, Bhargava S, Fosså A (2023)
Overall survival and causes of death in elderly patients with Hodgkin lymphoma: a Norwegian population-based case-control study
Haematologica (in press)
DOI 10.3324/haematol.2023.283721, PubMed 37881879

Ludvigsen M, Campbell AJ, Enemark MB, Hybel TE, Karjalainen-Lindsberg ML, Beiske K, Bjerre M, Pedersen LM, Holte H, Leppä S, Jørgensen JM, Honoré B (2023)
Proteomics uncovers molecular features for relapse risk stratification in patients with diffuse large B-cell lymphoma
Blood Cancer J, 13 (1), 161
DOI 10.1038/s41408-023-00931-6, PubMed 37884514

Luminari S, Fossa A, Trotman J, Molin D, d'Amore F, Enblad G, Berkahn L, Barrington SF, Radford J, Federico M, Kirkwood AA, Johnson PWM (2023)
Long-Term Follow-Up of the Response-Adjusted Therapy for Advanced Hodgkin Lymphoma Trial
J Clin Oncol, 42 (1), 13-18
DOI 10.1200/JCO.23.01177, PubMed 37883739

Mauz-Körholz C, Landman-Parker J, Fernández-Teijeiro A, Attarbaschi A, Balwierz W, Bartelt JM, Beishuizen A, Boudjemaa S, Cepelova M, Ceppi F, Claviez A, Daw S, Dieckmann K, Fosså A, Gattenlöhner S, Georgi T, Hjalgrim LL, Hraskova A, Karlén J, Kurch L, Leblanc T, Mann G, Montravers F, Pears J, Pelz T et al. (2023)
Response-adapted omission of radiotherapy in children and adolescents with early-stage classical Hodgkin lymphoma and an adequate response to vincristine, etoposide, prednisone, and doxorubicin (EuroNet-PHL-C1): a titration study
Lancet Oncol, 24 (3), 252-261
DOI 10.1016/S1470-2045(23)00019-0, PubMed 36858722

Ramsower CA, Rosenthal A, Robetorye RS, Mwangi R, Maurer M, Villa D, McDonnell T, Feldman A, Cohen JB, Habermann T, Campo E, Clot G, Bühler MM, Kulis M, Martin-Subero JI, Giné E, Cook JR, Hill B, Raess PW, Beiske KH, Reichart A, Hartmann S, Holte H, Scott D, Rimsza L (2023)
Evaluation of clinical parameters and biomarkers in older, untreated mantle cell lymphoma patients receiving bendamustine-rituximab
Br J Haematol, 204 (1), 160-170
DOI 10.1111/bjh.19153, PubMed 37881141

Salim R, Husby S, Winther Eskelund C, Scott DW, Holte H, Kolstad A, Räty R, Ek S, Jerkeman M, Geisler C, Sommer Kristensen L, Dahl M, Grønbæk K (2023)
Exploring new prognostic biomarkers in Mantle Cell Lymphoma: a comparison of the circSCORE and the MCL35 score
Leuk Lymphoma, 64 (8), 1414-1423
DOI 10.1080/10428194.2023.2216819, PubMed 37259807

Sletten OJ, Aalen JM, Smiseth OA, Khan FH, Fosså A, Kiserud CE, Villegas-Martinez M, Hisdal J, Remme EW, Skulstad H (2023)
Mental Stress Reduces Left Ventricular Strain: Can It Lead to Misinterpretation of Cancer Therapy-Related Cardiac Dysfunction?
J Am Soc Echocardiogr (in press)
DOI 10.1016/j.echo.2023.11.010, PubMed 37981246

Spasevska I, Sharma A, Steen CB, Josefsson SE, Blaker YN, Kolstad A, Rustad EH, Meyer S, Isaksen K, Chellappa S, Kushekhar K, Beiske K, Førsund MS, Spetalen S, Holte H, Østenstad B, Brodtkorb M, Kimby E, Olweus J, Taskén K, Newman AM, Lorenz S, Smeland EB, Alizadeh AA, Huse K et al. (2023)
Diversity of intratumoral regulatory T cells in B-cell non-Hodgkin lymphoma
Blood Adv, 7 (23), 7216-7230
DOI 10.1182/bloodadvances.2023010158, PubMed 37695745

Publications 2022

Callesen LB, Hamfjord J, Boysen AK, Pallisgaard N, Guren TK, Kure EH, Spindler KG (2022)
Circulating tumour DNA and its clinical utility in predicting treatment response or survival in patients with metastatic colorectal cancer: a systematic review and meta-analysis
Br J Cancer, 127 (3), 500-513
DOI 10.1038/s41416-022-01816-4, PubMed 35440666

Callesen LB, Takacova T, Hamfjord J, Würschmidt F, Oldhafer KJ, Brüning R, Arnold D, Spindler KG (2022)
Circulating DNA in patients undergoing loco-regional treatment of colorectal cancer metastases: a systematic review and meta-analysis
Ther Adv Med Oncol, 14, 17588359221133171
DOI 10.1177/17588359221133171, PubMed 36339929

Dahl M, Husby S, Eskelund CW, Besenbacher S, Fjelstrup S, Côme C, Ek S, Kolstad A, Räty R, Jerkeman M, Geisler CH, Kjems J, Kristensen LS, Grønbæk K (2022)
Correction: Expression patterns and prognostic potential of circular RNAs in mantle cell lymphoma: a study of younger patients from the MCL2 and MCL3 clinical trials
Leukemia, 36 (4), 1198
DOI 10.1038/s41375-022-01526-z, PubMed 35181760

Eikeland SA, Smeland KB, Brekke M, Kiserud CE, Fosså A (2022)
Late-effect awareness and follow-up of cancer in general practice
Scand J Prim Health Care, 40 (3), 360-369
DOI 10.1080/02813432.2022.2139457, PubMed 36380478

Khadse A, Haakensen VD, Silwal-Pandit L, Hamfjord J, Micke P, Botling J, Brustugun OT, Lingjærde OC, Helland Å, Kure EH (2022)
Prognostic Significance of the Loss of Heterozygosity of KRAS in Early-Stage Lung Adenocarcinoma
Front Oncol, 12, 873532
DOI 10.3389/fonc.2022.873532, PubMed 35574381

Kiserud CE, Lockmer S, Baerug I, Dahl AA, Kimby E, Østenstad B (2022)
Health-related quality of life and chronic fatigue in long-term survivors of indolent lymphoma - a comparison with normative data
Leuk Lymphoma, 64 (2), 349-355
DOI 10.1080/10428194.2022.2142050, PubMed 36342349

Larsen TL, Garresori H, Brekke J, Enden T, Frøen H, Jacobsen EM, Quist-Paulsen P, Porojnicu AC, Ree AH, Torfoss D, Osvik Velle E, Skuterud Wik H, Ghanima W, Sandset PM, Dahm AEA (2022)
Low dose apixaban as secondary prophylaxis of venous thromboembolism in cancer patients - 30 months follow-up
J Thromb Haemost, 20 (5), 1166-1181
DOI 10.1111/jth.15666, PubMed 35114046

Larsen TL, Garresori H, Brekke J, Enden T, Frøen H, Jacobsen EM, Quist-Paulsen P, Porojnicu AC, Ree AH, Torfoss D, Velle EO, Wik HS, Ghanima W, Sandset PM, Dahm AEA (2022)
"Low dose apixaban as secondary prophylaxis of venous thromboembolism in cancer patients - 30 months follow-up": Reply
J Thromb Haemost, 20 (8), 1937-1939
DOI 10.1111/jth.15774, PubMed 35859282

Larsen TL, Ghanima W, Sandset PM, Frøen H, Jacobsen EM, Torfoss D, Dahm AEA (2022)
[Factor Xa inhibitors in the prevention and treatment of venous thromboembolism in cancer patients]
Tidsskr Nor Laegeforen, 142 (1)
DOI 10.4045/tidsskr.22.0228, PubMed 36655971

Løndalen A, Blakkisrud J, Revheim ME, Dahle J, Kolstad A, Stokke C (2022)
FDG PET/CT and Dosimetric Studies of ¹⁷⁷Lu-Lilotomab Satetraxetan in a First-in-Human Trial for Relapsed Indolent non-Hodgkin Lymphoma-Are We Hitting the Target?
Mol Imaging Biol, 24 (5), 807-817
DOI 10.1007/s11307-022-01731-3, PubMed 35486292

Meriranta L, Alkodsi A, Pasanen A, Lepistö M, Mapar P, Blaker YN, Jørgensen J, Karjalainen-Lindsberg ML, Fiskvik I, Mikalsen LTG, Autio M, Björkholm M, Jerkeman M, Fluge Ø, Brown P, Jyrkkiö S, Holte H, Pitkänen E, Ellonen P, Leppä S (2022)
Molecular features encoded in the ctDNA reveal heterogeneity and predict outcome in high-risk aggressive B-cell lymphoma
Blood, 139 (12), 1863-1877
DOI 10.1182/blood.2021012852, PubMed 34932792

Nielsen HJ, Nedrebø BG, Fosså A, Andersen JR, Assmus J, Dagsland VH, Dankel SN, Gudbrandsen OA, Fernø J, Hjellestad I, Hjermstad MJ, Kolotkin RL, Thorsen HL, Mellgren G, Flølo TN (2022)
Seven-year trajectories of body weight, quality of life and comorbidities following Roux-en-Y gastric bypass and sleeve gastrectomy
Int J Obes (Lond), 46 (4), 739-749
DOI 10.1038/s41366-021-01028-5, PubMed 34974544

Pierson SK, Katz L, Williams R, Mumau M, Gonzalez M, Guzman S, Rubenstein A, Oromendia AB, Beineke P, Fosså A, van Rhee F, Fajgenbaum DC (2022)
CXCL13 is a predictive biomarker in idiopathic multicentric Castleman disease
Nat Commun, 13 (1), 7236
DOI 10.1038/s41467-022-34873-7, PubMed 36433996

Riis M, Csanaky G, Lehne G, Tangerud A (2022)
Anaplastic large cell lymphoma, ALK-negative of the breast diagnosed a short time after removal of breast implant in a patient with breast carcinoma: diagnostic and therapeutic considerations
BMJ Case Rep, 15 (3)
DOI 10.1136/bcr-2021-248232, PubMed 35236698

Riise J, Meyer S, Blaas I, Chopra A, Tran TT, Delic-Sarac M, Hestdalen ML, Brodin E, Rustad EH, Dai KZ, Vaage JT, Nissen-Meyer LSH, Sund F, Wader KF, Bjornevik AT, Meyer PA, Nygaard GO, König M, Smeland S, Lund-Johansen F, Olweus J, Kolstad A (2022)
Rituximab-treated patients with lymphoma develop strong CD8 T-cell responses following COVID-19 vaccination
Br J Haematol, 197 (6), 697-708
DOI 10.1111/bjh.18149, PubMed 35254660

Smeland K, Holte H, Fagerli UM, Bersvendsen H, Hjermstad MJ, Loge JH, Murbrach K, Linnsund MD, Fluge O, Stenehjem JS, Lund MB, Kvaloy S, Kiserud CE (2022)
Total late effect burden in long-term lymphoma survivors after high-dose therapy with autologous stem-cell transplant and its effect on health-related quality of life
Haematologica, 107 (11), 2698-2707
DOI 10.3324/haematol.2021.280413, PubMed 35484681

Vajavaara H, Leivonen SK, Jørgensen J, Holte H, Leppä S (2022)
Low lymphocyte-to-monocyte ratio predicts poor outcome in high-risk aggressive large B-cell lymphoma
EJHaem, 3 (3), 681-687
DOI 10.1002/jha2.409, PubMed 36051040

Publications 2021

Ali M, Giannakopoulou E, Li Y, Lehander M, Virding Culleton S, Yang W, Knetter C, Odabasi MC, Bollineni RC, Yang X, Foldvari Z, Böschen ML, Taraldsrud E, Strønen E, Toebes M, Hillen A, Mazzi S, de Ru AH, Janssen GMC, Kolstad A, Tjønnfjord GE, Lie BA, Griffioen M, Lehmann S, Osnes LT et al. (2021)
T cells targeted to TdT kill leukemic lymphoblasts while sparing normal lymphocytes
Nat Biotechnol, 40 (4), 488-498
DOI 10.1038/s41587-021-01089-x, PubMed 34873326

Alonso-Álvarez S, Manni M, Montoto S, Sarkozy C, Morschhauser F, Wondergem MJ, Guarini A, Magnano L, Alcoceba M, Chamuleau M, Galimberti S, Gomes da Silva M, Holte H, Zucca E, Lockmer S, Aurer I, Marcheselli L, Stepanishyna Y, Caballero Barrigón MD, Salles G, Federico M (2021)
Primary refractory follicular lymphoma: a poor outcome entity with high risk of transformation to aggressive B cell lymphoma
Eur J Cancer, 157, 132-139
DOI 10.1016/j.ejca.2021.08.005, PubMed 34508995

Autio M, Leivonen SK, Brück O, Mustjoki S, Mészáros Jørgensen J, Karjalainen-Lindsberg ML, Beiske K, Holte H, Pellinen T, Leppä S (2021)
Immune cell constitution in the tumor microenvironment predicts the outcome in diffuse large B-cell lymphoma
Haematologica, 106 (3), 718-729
DOI 10.3324/haematol.2019.243626, PubMed 32079690

Bishop MR, Dickinson M, Purtill D, Barba P, Santoro A, Hamad N, Kato K, Sureda A, Greil R, Thieblemont C, Morschhauser F, Janz M, Flinn I, Rabitsch W, Kwong YL, Kersten MJ, Minnema MC, Holte H, Chan EHL, Martinez-Lopez J, Müller AMS, Maziarz RT, McGuirk JP, Bachy E, Le Gouill S et al. (2021)
Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma
N Engl J Med, 386 (7), 629-639
DOI 10.1056/NEJMoa2116596, PubMed 34904798

Blakkisrud J, Løndalen A, Dahle J, Martinsen AC, Kolstad A, Stokke C (2021)
Myelosuppression in patients treated with ¹⁷⁷Lutetium-lilotomab satetraxetan can be predicted with absorbed dose to the red marrow as the only variable
Acta Oncol, 60 (11), 1481-1488
DOI 10.1080/0284186X.2021.1959635, PubMed 34425735

Dahl M, Husby S, Eskelund CW, Besenbacher S, Fjelstrup S, Côme C, Ek S, Kolstad A, Räty R, Jerkeman M, Geisler CH, Kjems J, Kristensen LS, Grønbæk K (2021)
Expression patterns and prognostic potential of circular RNAs in mantle cell lymphoma: a study of younger patients from the MCL2 and MCL3 clinical trials
Leukemia, 36 (1), 177-188
DOI 10.1038/s41375-021-01311-4, PubMed 34244612

Eikeland SA, Smeland KB, Mols F, Fagerli UM, Bersvendsen HS, Kiserud CE, Fosså A (2021)
Chemotherapy-induced peripheral neuropathy after modern treatment of Hodgkin's lymphoma; symptom burden and quality of life
Acta Oncol, 60 (7), 911-920
DOI 10.1080/0284186X.2021.1917776, PubMed 33905285

Fowler NH, Dickinson M, Dreyling M, Martinez-Lopez J, Kolstad A, Butler J, Ghosh M, Popplewell L, Chavez JC, Bachy E, Kato K, Harigae H, Kersten MJ, Andreadis C, Riedell PA, Ho PJ, Pérez-Simón JA, Chen AI, Nastoupil LJ, von Tresckow B, Ferreri AJM, Teshima T, Patten PEM, McGuirk JP, Petzer AL et al. (2021)
Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial
Nat Med, 28 (2), 325-332
DOI 10.1038/s41591-021-01622-0, PubMed 34921238

Hamfjord J, Guren TK, Glimelius B, Sorbye H, Pfeiffer P, Dajani O, Lingjaerde OC, Tveit KM, Pallisgaard N, Spindler KG, Kure EH (2021)
Clinicopathological factors associated with tumour-specific mutation detection in plasma of patients with RAS-mutated or BRAF-mutated metastatic colorectal cancer
Int J Cancer, 149 (6), 1385-1397
DOI 10.1002/ijc.33672, PubMed 33961700

Hamfjord J, Myklebust TÅ, Larsen IK, Kure EH, Glimelius B, Guren TK, Tveit KM, Guren MG (2021)
Survival Trends of Right- and Left-Sided Colon Cancer across Four Decades: A Norwegian Population-Based Study
Cancer Epidemiol Biomarkers Prev, 31 (2), 342-351
DOI 10.1158/1055-9965.EPI-21-0555, PubMed 34853022

Hjermstad MJ, Hamfjord J, Aass N, Dajani O, Lundeby T, Wester T, Kaasa S (2021)
Using Process Indicators to Monitor Documentation of Patient-Centred Variables in an Integrated Oncology and Palliative Care Pathway-Results from a Cluster Randomized Trial
Cancers (Basel), 13 (9)
DOI 10.3390/cancers13092194, PubMed 34063594

Hoel F, Hoel A, Pettersen IK, Rekeland IG, Risa K, Alme K, Sørland K, Fosså A, Lien K, Herder I, Thürmer HL, Gotaas ME, Schäfer C, Berge RK, Sommerfelt K, Marti HP, Dahl O, Mella O, Fluge Ø, Tronstad KJ (2021)
A map of metabolic phenotypes in patients with myalgic encephalomyelitis/chronic fatigue syndrome
JCI Insight, 6 (16)
DOI 10.1172/jci.insight.149217, PubMed 34423789

Isaksen KT, Mastroianni MA, Rinde M, Rusten LS, Barzenje DA, Ramslien LF, Slaaen M, Jerm MB, Smeland EB, Rostoft S, Liestøl K, Brodtkorb M, Holte H (2021)
A simplified frailty score predicts survival and can aid treatment-intensity decisions in older patients with DLBCL
Blood Adv, 5 (22), 4771-4782
DOI 10.1182/bloodadvances.2021004777, PubMed 34543384

Kurch L, Mauz-Körholz C, Fosså A, Georgi TW, Kluge R, Bartelt JM, Kunze C, Wohlgemuth WA, Pelz T, Vordermark D, Plößl S, Hasenclever D, Sabri O, Landman-Parker J, Wallace WH, Karlen J, Fernández-Teijeiro A, Cepelova M, Klekawka T, Løndalen AM, Steiner D, Krombach G, Attarbaschi A, Hoffmann M, Ceppi F et al. (2021)
Assessment of Waldeyer's ring in pediatric and adolescent Hodgkin lymphoma patients-Importance of multimodality imaging: Results from the EuroNet-PHL-C1 trial
Pediatr Blood Cancer, 68 (4), e28903
DOI 10.1002/pbc.28903, PubMed 33538093

Lindberg Å, Eskelund CW, Albertsson-Lindblad A, Kolstad A, Laurell A, Räty R, Grønbaek K, Geisler CH, Jerkeman M (2021)
Pre-treatment health-related quality of life parameters have prognostic impact in patients >65 years with newly diagnosed mantle cell lymphoma: The Nordic Lymphoma Group MCL4 (LENA-BERIT) experience
Hematol Oncol, 40 (1), 22-30
DOI 10.1002/hon.2940, PubMed 34713465

Lokhande L, Kuci Emruli V, Eskelund CW, Kolstad A, Hutchings M, Räty R, Niemann CU, Grønbaek K, Jerkeman M, Ek S (2021)
Serum proteome modulations upon treatment provides biological insight on response to treatment in relapsed mantle cell lymphoma
Cancer Rep (Hoboken), 5 (7), e1524
DOI 10.1002/cnr2.1524, PubMed 34319003

Mauz-Körholz C, Landman-Parker J, Balwierz W, Ammann RA, Anderson RA, Attarbaschi A, Bartelt JM, Beishuizen A, Boudjemaa S, Cepelova M, Claviez A, Daw S, Dieckmann K, Fernández-Teijeiro A, Fosså A, Gattenlöhner S, Georgi T, Hjalgrim LL, Hraskova A, Karlén J, Kluge R, Kurch L, Leblanc T, Mann G, Montravers F et al. (2021)
Response-adapted omission of radiotherapy and comparison of consolidation chemotherapy in children and adolescents with intermediate-stage and advanced-stage classical Hodgkin lymphoma (EuroNet-PHL-C1): a titration study with an open-label, embedded, multinational, non-inferiority, randomised controlled trial
Lancet Oncol, 23 (1), 125-137
DOI 10.1016/S1470-2045(21)00470-8, PubMed 34895479

Merrien M, Wasik AM, Ljung E, Morsy MHA, de Matos Rodrigues J, Carlsten M, Rassidakis GZ, Christensson B, Kolstad A, Jerkeman M, Ek S, Herold N, Wahlin BE, Sander B (2021)
Clinical and biological impact of SAMHD1 expression in mantle cell lymphoma
Virchows Arch, 480 (3), 655-666
DOI 10.1007/s00428-021-03228-w, PubMed 34738194

Pierson SK, Shenoy S, Oromendia AB, Gorzewski AM, Langan Pai RA, Nabel CS, Ruth JR, Parente SAT, Arenas DJ, Guilfoyle M, Reddy M, Weinblatt M, Shadick N, Bower M, Pria AD, Masaki Y, Katz L, Mezey J, Beineke P, Lee D, Tendler C, Kambayashi T, Fosså A, van Rhee F, Fajgenbaum DC (2021)
Discovery and validation of a novel subgroup and therapeutic target in idiopathic multicentric Castleman disease
Blood Adv, 5 (17), 3445-3456
DOI 10.1182/bloodadvances.2020004016, PubMed 34438448

Rodrigues JM, Nikkarinen A, Hollander P, Weibull CE, Räty R, Kolstad A, Amini RM, Porwit A, Jerkeman M, Ek S, Glimelius I (2021)
Infiltration of CD163-, PD-L1- and FoxP3-positive cells adversely affects outcome in patients with mantle cell lymphoma independent of established risk factors
Br J Haematol, 193 (3), 520-531
DOI 10.1111/bjh.17366, PubMed 33686666

Schuster SJ, Tam CS, Borchmann P, Worel N, McGuirk JP, Holte H, Waller EK, Jaglowski S, Bishop MR, Damon LE, Foley SR, Westin JR, Fleury I, Ho PJ, Mielke S, Teshima T, Janakiram M, Hsu JM, Izutsu K, Kersten MJ, Ghosh M, Wagner-Johnston N, Kato K, Corradini P, Martinez-Prieto M et al. (2021)
Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study
Lancet Oncol, 22 (10), 1403-1415
DOI 10.1016/S1470-2045(21)00375-2, PubMed 34516954

Vajavaara H, Ekeblad F, Holte H, Jorgensen J, Leivonen SK, Berglund M, Kamper P, Moller HJ, D'Amore F, Molin D, Enblad G, Ludvigsen M, Glimelius I, Leppa S (2021)
Prognostic impact of soluble CD163 in patients with diffuse large B-cell lymphoma
Haematologica, 106 (9), 2502-2506
DOI 10.3324/haematol.2020.278182, PubMed 33764002

Vajavaara H, Mortensen JB, Leivonen SK, Hansen IM, Ludvigsen M, Holte H, Jørgensen J, Bjerre M, d'Amore F, Leppä S (2021)
Soluble PD-1 but Not PD-L1 Levels Predict Poor Outcome in Patients with High-Risk Diffuse Large B-Cell Lymphoma
Cancers (Basel), 13 (3)
DOI 10.3390/cancers13030398, PubMed 33499013

Publications 2020

Ask EH, Tschan-Plessl A, Gjerdingen TJ, Sætersmoen ML, Hoel HJ, Wiiger MT, Olweus J, Wahlin BE, Lingjærde OC, Horowitz A, Cashen AF, Watkins M, Fehniger TA, Holte H, Kolstad A, Malmberg KJ (2020)
A Systemic Protein Deviation Score Linked to PD-1⁺ CD8⁺ T Cell Expansion That Predicts Overall Survival in Diffuse Large B Cell Lymphoma
Med, 2 (2), 180-195.e5
DOI 10.1016/j.medj.2020.10.006, PubMed 35590201

Bersvendsen HS, Haugnes HS, Dahl AA, Fagerli UM, Fluge Ø, Holte H, Wilsgaard T, Smeland KB, Kiserud CE (2020)
Sexual dysfunction is prevalent in female lymphoma survivors after autologous stem-cell transplantation and is associated with younger age, chronic fatigue, and mental distress
Bone Marrow Transplant, 56 (4), 968-970
DOI 10.1038/s41409-020-01098-5, PubMed 33139869

Eskelund CW, Dimopoulos K, Kolstad A, Glimelius I, Räty R, Gjerdrum LMR, Sonnevi K, Josefsson P, Nilsson-Ehle H, Bentzen HHN, Fagerli UM, Kuittinen O, Haaber J, Niemann CU, Pedersen LB, Larsen MT, Geisler CH, Hutchings M, Jerkeman M, Grønbæk K (2020)
Detailed Long-Term Follow-Up of Patients Who Relapsed After the Nordic Mantle Cell Lymphoma Trials: MCL2 and MCL3
Hemasphere, 5 (1), e510
DOI 10.1097/HS9.0000000000000510, PubMed 33364550

Eskelund CW, Husby S, Favero F, Klausen TW, Rodriguez-Gonzalez FG, Kolstad A, Pedersen LB, Räty RK, Geisler CH, Jerkeman M, Weischenfeldt J, Grønbæk K (2020)
Clonal hematopoiesis evolves from pretreatment clones and stabilizes after end of chemotherapy in patients with MCL
Blood, 135 (22), 2000-2004
DOI 10.1182/blood.2019003539, PubMed 32181815

Fajgenbaum DC, Wu D, Goodman A, Wong R, Chadburn A, Nasta S, Srkalovic G, Mukherjee S, Leitch H, Jayanthan R, Ferrero S, Sato Y, Schey S, Dispenzieri A, Oksenhendler E, Zinzani PL, Lechowicz MJ, Hoffmann C, Pemmaraju N, Bagg A, Fossa A, Lim MS, van Rhee F, Castleman Disease Collaborative Network Scientific Advisory Board diagnostic criteria international working group and treatment guidelines international working group (2020)
Insufficient evidence exists to use histopathologic subtype to guide treatment of idiopathic multicentric Castleman disease
Am J Hematol, 95 (12), 1553-1561
DOI 10.1002/ajh.25992, PubMed 32894785

Fosså A, Smeland KH, Fluge Ø, Tronstad KJ, Loge JH, Midttun Ø, Ueland PM, Kiserud CE (2020)
Metabolic analysis of amino acids and vitamin B6 pathways in lymphoma survivors with cancer related chronic fatigue
PLoS One, 15 (1), e0227384
DOI 10.1371/journal.pone.0227384, PubMed 31923274

Hannevik TL, Brekke J, Enden T, Frøen H, Garresori H, Jacobsen EM, Paulsen PQ, Porojnicu AC, Ree AH, Torfoss D, Velle EO, Wik HS, Ghanima W, Sandset PM, Dahm AEA (2020)
Thrombosis and bleedings in a cohort of cancer patients treated with apixaban for venous thromboembolism
Thromb Res, 196, 238-244
DOI 10.1016/j.thromres.2020.08.042, PubMed 32919178

Isaksen KT, Beiske K, Smeland EB, Jørgensen J, Brodtkorb M, Myklebust JH, Jerkeman M, Meriranta L, Karjalainen-Lindsberg ML, Leppä S, Scott DW, Holte H, Blaker YN (2020)
The DLBCL90 gene-expression assay identifies double-hit lymphomas with high sensitivity in patients from two phase II clinical trials with high-risk diffuse large B-cell lymphoma
EJHaem, 2 (1), 104-108
DOI 10.1002/jha2.109, PubMed 35846101

Jakobsen LH, Ellin F, Smeland KB, Wästerlid T, Christensen JH, Jørgensen JM, Josefsson PL, Øvlisen AK, Holte H, Blaker YN, Grauslund JH, Bjørn J, Molin D, Lagerlöf I, Smedby KE, Colvin K, Thanarajasingam G, Maurer MJ, Habermann TM, Song KW, Zhu KY, Gerrie AS, Cheah CY, El-Galaly TC (2020)
Minimal relapse risk and early normalization of survival for patients with Burkitt lymphoma treated with intensive immunochemotherapy: an international study of 264 real-world patients
Br J Haematol, 189 (4), 661-671
DOI 10.1111/bjh.16425, PubMed 32017050

Kimby E, Lockmer S, Holte H, Hagberg H, Wahlin BE, Brown P, Østenstad B (2020)
The simplified follicular lymphoma PRIMA-prognostic index is useful in patients with first-line chemo-free rituximab-based therapy
Br J Haematol, 191 (5), 738-747
DOI 10.1111/bjh.16692, PubMed 32410260

Kluge R, Wittig T, Georgi TW, Kurch L, Sabri O, Wallace WH, Klekawka T, Fernández-Teijeiro A, Ceppi F, Karlén J, Pears J, Cepelová M, Fosså A, Beishuizen A, Hjalgrim LL, Körholz D, Mauz-Körholz C, Hasenclever D (2020)
Comparison of Interim PET Response to Second-Line Versus First-Line Treatment in Classic Hodgkin Lymphoma: Contribution to the Development of Response Criteria for Relapsed or Progressive Disease
J Nucl Med, 62 (3), 338-341
DOI 10.2967/jnumed.120.247924, PubMed 32764122

Kolstad A, Illidge T, Bolstad N, Spetalen S, Madsbu U, Stokke C, Blakkisrud J, Løndalen A, O'Rourke N, Beasley M, Jurczak W, Fagerli UM, Kaščák M, Bayne M, Obr A, Dahle J, Rojkjaer L, Pascal V, Holte H (2020)
Phase 1/2a study of 177Lu-lilotomab satetraxetan in relapsed/refractory indolent non-Hodgkin lymphoma
Blood Adv, 4 (17), 4091-4101
DOI 10.1182/bloodadvances.2020002583, PubMed 32877524

Leppä S, Jørgensen J, Tierens A, Meriranta L, Østlie I, de Nully Brown P, Fagerli UM, Larsen TS, Mannisto S, Munksgaard L, Maisenhölder M, Vasala K, Meyer P, Jerkeman M, Björkholm M, Fluge Ø, Jyrkkiö S, Liestøl K, Ralfkiaer E, Spetalen S, Beiske K, Karjalainen-Lindsberg ML, Holte H (2020)
Patients with high-risk DLBCL benefit from dose-dense immunochemotherapy combined with early systemic CNS prophylaxis
Blood Adv, 4 (9), 1906-1915
DOI 10.1182/bloodadvances.2020001518, PubMed 32380536

Lokhande L, Kuci Emruli V, Kolstad A, Hutchings M, Räty R, Jerkeman M, Ek S (2020)
Immune-related protein signature in serum stratify relapsed mantle cell lymphoma patients based on risk
BMC Cancer, 20 (1), 1202
DOI 10.1186/s12885-020-07678-4, PubMed 33287742

Løndalen A, Blakkisrud J, Revheim ME, Madsbu UE, Dahle J, Kolstad A, Stokke C (2020)
FDG PET/CT parameters and correlations with tumor-absorbed doses in a phase 1 trial of ¹⁷⁷Lu-lilotomab satetraxetan for treatment of relapsed non-Hodgkin lymphoma
Eur J Nucl Med Mol Imaging, 48 (6), 1902-1914
DOI 10.1007/s00259-020-05098-x, PubMed 33196921

Maziarz RT, Waller EK, Jaeger U, Fleury I, McGuirk J, Holte H, Jaglowski S, Schuster SJ, Bishop MR, Westin JR, Mielke S, Teshima T, Bachanova V, Foley SR, Borchmann P, Salles GA, Zhang J, Tiwari R, Pacaud LB, Ma Q, Tam CS (2020)
Patient-reported long-term quality of life after tisagenlecleucel in relapsed/refractory diffuse large B-cell lymphoma
Blood Adv, 4 (4), 629-637
DOI 10.1182/bloodadvances.2019001026, PubMed 32074277

Maaland AF, Saidi A, Torgue J, Heyerdahl H, Stallons TAR, Kolstad A, Dahle J (2020)
Targeted alpha therapy for chronic lymphocytic leukaemia and non-Hodgkin's lymphoma with the anti-CD37 radioimmunoconjugate 212Pb-NNV003
PLoS One, 15 (3), e0230526
DOI 10.1371/journal.pone.0230526, PubMed 32187209

Pierson SK, Khor JS, Ziglar J, Liu A, Floess K, NaPier E, Gorzewski AM, Tamakloe MA, Powers V, Akhter F, Haljasmaa E, Jayanthan R, Rubenstein A, Repasky M, Elenitoba-Johnson K, Ruth J, Jacobs B, Streetly M, Angenendt L, Patier JL, Ferrero S, Zinzani PL, Terriou L, Casper C, Jaffe E et al. (2020)
ACCELERATE: A Patient-Powered Natural History Study Design Enabling Clinical and Therapeutic Discoveries in a Rare Disorder
Cell Rep Med, 1 (9), 100158
DOI 10.1016/j.xcrm.2020.100158, PubMed 33377129

Rekeland IG, Fosså A, Lande A, Ktoridou-Valen I, Sørland K, Holsen M, Tronstad KJ, Risa K, Alme K, Viken MK, Lie BA, Dahl O, Mella O, Fluge Ø (2020)
Intravenous Cyclophosphamide in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. An Open-Label Phase II Study
Front Med (Lausanne), 7, 162
DOI 10.3389/fmed.2020.00162, PubMed 32411717

Rodrigues JM, Hassan M, Freiburghaus C, Eskelund CW, Geisler C, Räty R, Kolstad A, Sundström C, Glimelius I, Grønbaek K, Kwiecinska A, Porwit A, Jerkeman M, Ek S (2020)
p53 is associated with high-risk and pinpoints TP53 missense mutations in mantle cell lymphoma
Br J Haematol, 191 (5), 796-805
DOI 10.1111/bjh.17023, PubMed 32748433

Tveiten H, Aukrust P, Lehne G, Rodriguez JR, Skjønsberg OH (2020)
Haemophagocytic lymphohistiocytosis in COVID-19 cases?
Tidsskr Nor Laegeforen, 140 (6)
DOI 10.4045/tidsskr.20.0240, PubMed 32321221

van Rhee F, Oksenhendler E, Srkalovic G, Voorhees P, Lim M, Dispenzieri A, Ide M, Parente S, Schey S, Streetly M, Wong R, Wu D, Maillard I, Brandstadter J, Munshi N, Bowne W, Elenitoba-Johnson KS, Fössa A, Lechowicz MJ, Chandrakasan S, Pierson SK, Greenway A, Nasta S, Yoshizaki K, Kurzrock R et al. (2020)
International evidence-based consensus diagnostic and treatment guidelines for unicentric Castleman disease
Blood Adv, 4 (23), 6039-6050
DOI 10.1182/bloodadvances.2020003334, PubMed 33284946

van Rhee F, Rossi JF, Simpson D, Fosså A, Dispenzieri A, Kuruvilla J, Goh YT, Cho SG, Capra M, Liu T, Casper C, Cavet J, Wong RS (2020)
Newly diagnosed and previously treated multicentric Castleman disease respond equally to siltuximab
Br J Haematol, 192 (1), e28-e31
DOI 10.1111/bjh.17177, PubMed 33128769

Wise JF, Nakken S, Steen CB, Vodák D, Trøen G, Johannessen B, Lingjærde OC, Hilden V, Blaker YN, Bai B, Aasheim LB, Pasanen A, Lorenz S, Sveen A, Lothe RA, Myklebost O, Leppä S, Meza-Zepeda LA, Beiske K, Lawrence MS, Hovig E, Myklebust JH, Smeland EB, Holte H (2020)
Mutational dynamics and immune evasion in diffuse large B-cell lymphoma explored in a relapse-enriched patient series
Blood Adv, 4 (9), 1859-1866
DOI 10.1182/bloodadvances.2019001325, PubMed 32374878

Publications 2019

Alkodsi A, Cervera A, Zhang K, Louhimo R, Meriranta L, Pasanen A, Leivonen SK, Holte H, Leppä S, Lehtonen R, Hautaniemi S (2019)
Distinct subtypes of diffuse large B-cell lymphoma defined by hypermutated genes
Leukemia, 33 (11), 2662-2672
DOI 10.1038/s41375-019-0509-6, PubMed 31186494

Bersvendsen HS, Haugnes HS, Dahl AA, Fagerli UM, Fluge Ø, Holte H, Seland M, Wilsgaard T, Smeland KB, Kiserud CE (2019)
Sexual function in long-term male lymphoma survivors after high-dose therapy with autologous stem-cell transplantation
Bone Marrow Transplant, 55 (5), 891-905
DOI 10.1038/s41409-019-0745-4, PubMed 31745250

Bersvendsen HS, Haugnes HS, Fagerli UM, Fluge Ø, Holte H, Smeland KB, Wilsgaard T, Kiserud CE (2019)
Lifestyle behavior among lymphoma survivors after high-dose therapy with autologous hematopoietic stem cell transplantation, assessed by patient-reported outcomes
Acta Oncol, 58 (5), 690-699
DOI 10.1080/0284186X.2018.1558370, PubMed 30696346

Biccler JL, Glimelius I, Eloranta S, Smeland KB, Brown PN, Jakobsen LH, Frederiksen H, Jerkeman M, Fosså A, Andersson TML, Holte H, Bøgsted M, El-Galaly TC, Smedby KE (2019)
Relapse Risk and Loss of Lifetime After Modern Combined Modality Treatment of Young Patients With Hodgkin Lymphoma: A Nordic Lymphoma Epidemiology Group Study
J Clin Oncol, 37 (9), 703-713
DOI 10.1200/JCO.18.01652, PubMed 30726176

Bishop MR, Maziarz RT, Waller EK, Jäger U, Westin JR, McGuirk JP, Fleury I, Holte H, Borchmann P, Del Corral C, Tiwari R, Anak Ö, Awasthi R, Pacaud L, Romanov VV, Schuster SJ (2019)
Tisagenlecleucel in relapsed/refractory diffuse large B-cell lymphoma patients without measurable disease at infusion
Blood Adv, 3 (14), 2230-2236
DOI 10.1182/bloodadvances.2019000151, PubMed 31332046

Ferrero S, Rossi D, Rinaldi A, Bruscaggin A, Spina V, Eskelund CW, Evangelista A, Moia R, Kwee I, Dahl C, Di Rocco A, Stefoni V, Diop F, Favini C, Ghione P, Mahmoud AM, Schipani M, Kolstad A, Barbero D, Novero D, Paulli M, Zamò A, Jerkeman M, da Silva MG, Santoro A et al. (2019)
KMT2D mutations and TP53 disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: a FIL study
Haematologica, 105 (6), 1604-1612
DOI 10.3324/haematol.2018.214056, PubMed 31537689

Fosså A, Smeland K, Fagerli UM, Galleberg RB, Bersvendsen HS, Holte H (2019)
Brentuximab vedotin in relapsed or refractory classical hodgkin lymphoma: real life experience in Norway 2011-2016
Acta Oncol, 59 (1), 101-105
DOI 10.1080/0284186X.2019.1652765, PubMed 31429371

Hamfjord J, Guren TK, Dajani O, Johansen JS, Glimelius B, Sorbye H, Pfeiffer P, Lingjærde OC, Tveit KM, Kure EH, Pallisgaard N, Spindler KG (2019)
Total circulating cell-free DNA as a prognostic biomarker in metastatic colorectal cancer before first-line oxaliplatin-based chemotherapy
Ann Oncol, 30 (7), 1088-1095
DOI 10.1093/annonc/mdz139, PubMed 31046124

Josefsson SE, Beiske K, Blaker YN, Førsund MS, Holte H, Østenstad B, Kimby E, Köksal H, Wälchli S, Bai B, Smeland EB, Levy R, Kolstad A, Huse K, Myklebust JH (2019)
TIGIT and PD-1 Mark Intratumoral T Cells with Reduced Effector Function in B-cell Non-Hodgkin Lymphoma
Cancer Immunol Res, 7 (3), 355-362
DOI 10.1158/2326-6066.CIR-18-0351, PubMed 30659053

Köksal H, Dillard P, Josefsson SE, Maggadottir SM, Pollmann S, Fåne A, Blaker YN, Beiske K, Huse K, Kolstad A, Holte H, Kvalheim G, Smeland EB, Myklebust JH, Inderberg EM, Wälchli S (2019)
Preclinical development of CD37CAR T-cell therapy for treatment of B-cell lymphoma
Blood Adv, 3 (8), 1230-1243
DOI 10.1182/bloodadvances.2018029678, PubMed 30979721

Lagerlöf I, Holte H, Glimelius I, Björkholm M, Enblad G, Erlanson M, Fluge Ø, Fohlin H, Fosså A, Goldkuhl C, Gustavsson A, Johansson AS, Linderoth J, Nome O, Palma M, Åkesson L, Østenstad B, Raud C, Glimelius B, Molin D (2019)
No excess long-term mortality in stage I-IIA Hodgkin lymphoma patients treated with ABVD and limited field radiotherapy
Br J Haematol, 188 (5), 685-691
DOI 10.1111/bjh.16232, PubMed 31612478

Lockmer S, Ren W, Brodtkorb M, Østenstad B, Wahlin BE, Pan-Hammarström Q, Kimby E (2019)
M7-FLIPI is not prognostic in follicular lymphoma patients with first-line rituximab chemo-free therapy
Br J Haematol, 188 (2), 259-267
DOI 10.1111/bjh.16159, PubMed 31423576

Lockmer S, Østenstad B, Hagberg H, Holte H, Wahlin BE, Wader KF, Smedby KE, Brown P, Kimby E (2019)
Reply to M. Sorigue et al
J Clin Oncol, 37 (9), 759-760
DOI 10.1200/JCO.18.02362, PubMed 30735430

Maaland AF, Heyerdahl H, O'Shea A, Eiriksdottir B, Pascal V, Andersen JT, Kolstad A, Dahle J (2019)
Targeting B-cell malignancies with the beta-emitting anti-CD37 radioimmunoconjugate ¹⁷⁷Lu-NNV003
Eur J Nucl Med Mol Imaging, 46 (11), 2311-2321
DOI 10.1007/s00259-019-04417-1, PubMed 31309259

Nabel CS, Sameroff S, Shilling D, Alapat D, Ruth JR, Kawano M, Sato Y, Stone K, Spetalen S, Valdivieso F, Feldman MD, Chadburn A, Fosså A, van Rhee F, Lipkin WI, Fajgenbaum DC (2019)
Virome capture sequencing does not identify active viral infection in unicentric and idiopathic multicentric Castleman disease
PLoS One, 14 (6), e0218660
DOI 10.1371/journal.pone.0218660, PubMed 31242229

Poeschel V, Held G, Ziepert M, Witzens-Harig M, Holte H, Thurner L, Borchmann P, Viardot A, Soekler M, Keller U, Schmidt C, Truemper L, Mahlberg R, Marks R, Hoeffkes HG, Metzner B, Dierlamm J, Frickhofen N, Haenel M, Neubauer A, Kneba M, Merli F, Tucci A, de Nully Brown P, Federico M et al. (2019)
Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial
Lancet, 394 (10216), 2271-2281
DOI 10.1016/S0140-6736(19)33008-9, PubMed 31868632

Simensen VC, Smeland KB, Kiserud CE, Dahl AA, Bersvendsen HS, Fluge Ø, Fagerli UM, Fosså A (2019)
Survivors' knowledge of their diagnosis, treatment and possible late adverse effects after autologous stem cell transplantation for lymphoma
Acta Oncol, 58 (9), 1315-1322
DOI 10.1080/0284186X.2019.1637538, PubMed 31286808

Steen CB, Leich E, Myklebust JH, Lockmer S, Wise JF, Wahlin BE, Østenstad B, Liestøl K, Kimby E, Rosenwald A, Smeland EB, Holte H, Lingjærde OC, Brodtkorb M (2019)
A clinico-molecular predictor identifies follicular lymphoma patients at risk of early transformation after first-line immunotherapy
Haematologica, 104 (10), e460-e464
DOI 10.3324/haematol.2018.209080, PubMed 30846496

Switlyk MD, Skeie AT, Lund-Iversen M, Østenstad B (2019)
Magnetic resonance imaging and ¹⁸F-fluorodeoxyglucose positron emission tomography/computed tomography findings in neurolymphomatosis: an uncommon presentation of diffuse large B cell lymphoma
Ann Hematol, 99 (1), 203-205
DOI 10.1007/s00277-019-03850-4, PubMed 31768676

Zucca E, Rondeau S, Vanazzi A, Østenstad B, Mey UJM, Rauch D, Wahlin BE, Hitz F, Hernberg M, Johansson AS, de Nully Brown P, Hagberg H, Ferreri AJM, Lohri A, Novak U, Zander T, Bersvendsen H, Bargetzi M, Mingrone W, Krasniqi F, Dirnhofer S, Hayoz S, Hawle H, Vilei SB, Ghielmini M et al. (2019)
Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapy
Blood, 134 (4), 353-362
DOI 10.1182/blood-2018-10-879643, PubMed 31101627

Publications 2018

Borchmann P, Fosså A, Długosz-Danecka M, Böll B, Dietlein M, Kobe C, Goergen H, Engert A (2018)
The Phase 3 Study ECHELON-1 Evaluating Brentuximab Vedotin in Patients With Newly Diagnosed Hodgkin Lymphoma Leaves Important Questions Unanswered
Hemasphere, 2 (3), e52
DOI 10.1097/HS9.0000000000000052, PubMed 31723777

Da Broi M, Jahr G, Beiske K, Holte H, Meling TR (2018)
Efficacy of the Nordic and the MSKCC chemotherapy protocols on the overall and progression-free survival in intracranial PCNSL
Blood Cells Mol Dis, 73, 25-32
DOI 10.1016/j.bcmd.2018.08.005, PubMed 30217760

Eichenauer DA, André M, Johnson P, Fossa A, Casasnovas O, Engert A (2018)
Controversies in the Treatment of Classical Hodgkin Lymphoma
Hemasphere, 2 (5), e149
DOI 10.1097/HS9.0000000000000149, PubMed 30887012

Eskelund CW, Albertsson-Lindblad A, Kolstad A, Laurell A, Räty R, Pedersen LB, Geisler CH, Jerkeman M, Grønbæk K (2018)
Lenalidomide plus bendamustine-rituximab does not overcome the adverse impact of TP53 mutations in mantle cell lymphoma
Haematologica, 103 (11), e541-e543
DOI 10.3324/haematol.2018.194399, PubMed 29794145

Federico M, Caballero Barrigón MD, Marcheselli L, Tarantino V, Manni M, Sarkozy C, Alonso-Álvarez S, Wondergem M, Cartron G, Lopez-Guillermo A, Issa D, Morschhauser F, Alcoceba M, Kimby E, Rusconi C, Chamuleau M, Holte H, Lockmer S, Montoto S, Gomes da Silva M, Aurer I, Zucca E, Paszkiewicz-Kozik E, Minoia C, Skrypets T et al. (2018)
Rituximab and the risk of transformation of follicular lymphoma: a retrospective pooled analysis
Lancet Haematol, 5 (8), e359-e367
DOI 10.1016/S2352-3026(18)30090-5, PubMed 30078408

Georgi TW, Kluge R, Kurch L, Chavdarova L, Hasenclever D, Stoevesandt D, Pelz T, Landman-Parker J, Wallace WH, Karlen J, Fernández-Teijeiro A, Cepelova M, Fosså A, Balwierz W, Attarbaschi A, Ammann RA, Pears J, Hraskova A, Uyttebroeck A, Beishuizen A, Dieckmann K, Leblanc T, Daw S, Baumann J, Körholz D et al. (2018)
¹⁸F-FDG PET Response of Skeletal (Bone Marrow and Bone) Involvement After Induction Chemotherapy in Pediatric Hodgkin Lymphoma: Are Specific Response Criteria Required?
J Nucl Med, 59 (10), 1524-1530
DOI 10.2967/jnumed.117.205633, PubMed 29653979

Holte H, Beiske K, Boyle M, Trøen G, Blaker YN, Myklebust J, Kvaløy S, Rosenwald A, Lingjaerde OC, Rimsza LM, Smeland EB, Scott DW, Kolstad A (2018)
The MCL35 gene expression proliferation assay predicts high-risk MCL patients in a Norwegian cohort of younger patients given intensive first line therapy
Br J Haematol, 183 (2), 225-234
DOI 10.1111/bjh.15518, PubMed 30080252

Jahr G, Broi MD, Holte H, Beiske K, Meling TR (2018)
Evaluation of Memorial Sloan-Kettering Cancer Center and International Extranodal Lymphoma Study Group prognostic scoring systems to predict Overall Survival in intracranial Primary CNS lymphoma
Brain Behav, 8 (3), e00928
DOI 10.1002/brb3.928, PubMed 29541540

Jahr G, Da Broi M, Holte H, Beiske K, Meling TR (2018)
The role of surgery in intracranial PCNSL
Neurosurg Rev, 41 (4), 1037-1044
DOI 10.1007/s10143-018-0946-0, PubMed 29383600

Lockmer S, Østenstad B, Hagberg H, Holte H, Johansson AS, Wahlin BE, Wader KF, Steen CB, Meyer P, Maisenhølder M, Smedby KE, Brown P, Kimby E (2018)
Chemotherapy-Free Initial Treatment of Advanced Indolent Lymphoma Has Durable Effect With Low Toxicity: Results From Two Nordic Lymphoma Group Trials With More Than 10 Years of Follow-Up
J Clin Oncol, 36 (33), 3315-+
DOI 10.1200/JCO.18.00262, PubMed 30285560

Meling TR, Latysheva A, Da Broi M, Jahr G, Holte H, Beiske K, Emblem KE (2018)
Is deep brain involvement in intracranial primary central nervous system lymphoma of importance for penetration of chemotherapeutic agents?
Neuroradiology, 60 (7), 703-713
DOI 10.1007/s00234-018-2038-9, PubMed 29804159

Mottok A, Wright G, Rosenwald A, Ott G, Ramsower C, Campo E, Braziel RM, Delabie J, Weisenburger DD, Song JY, Chan WC, Cook JR, Fu K, Greiner T, Smeland E, Holte H, Savage KJ, Glinsmann-Gibson BJ, Gascoyne RD, Staudt LM, Jaffe ES, Connors JM, Scott DW, Steidl C, Rimsza LM (2018)
Molecular classification of primary mediastinal large B-cell lymphoma using routinely available tissue specimens
Blood, 132 (22), 2401-2405
DOI 10.1182/blood-2018-05-851154, PubMed 30257882

Rauert-Wunderlich H, Mottok A, Scott DW, Rimsza LM, Ott G, Klapper W, Unterhalt M, Kluin-Nelemans HC, Hermine O, Hartmann S, Thorns C, Rymkiewicz G, Holte H, Dreyling M, Hoster E, Rosenwald A (2018)
Validation of the MCL35 gene expression proliferation assay in randomized trials of the European Mantle Cell Lymphoma Network
Br J Haematol, 184 (4), 616-624
DOI 10.1111/bjh.15519, PubMed 30095158

Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, Jäger U, Jaglowski S, Andreadis C, Westin JR, Fleury I, Bachanova V, Foley SR, Ho PJ, Mielke S, Magenau JM, Holte H, Pantano S, Pacaud LB, Awasthi R, Chu J, Anak Ö, Salles G, Maziarz RT, JULIET Investigators (2018)
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
N Engl J Med, 380 (1), 45-56
DOI 10.1056/NEJMoa1804980, PubMed 30501490

Smeland KB, Loge JH, Aass HCD, Aspelin T, Bersvendsen H, Bolstad N, Fagerli UM, Falk RS, Fluge Ø, Fosså A, Holte H, Lund MB, Murbræch K, Reinertsen KV, Stenehjem JS, Kiserud CE (2018)
Chronic fatigue is highly prevalent in survivors of autologous stem cell transplantation and associated with IL-6, neuroticism, cardiorespiratory fitness, and obesity
Bone Marrow Transplant, 54 (4), 607-610
DOI 10.1038/s41409-018-0342-y, PubMed 30262906

Stokke C, Blakkisrud J, Løndalen A, Dahle J, Martinsen ACT, Holte H, Kolstad A (2018)
Pre-dosing with lilotomab prior to therapy with ¹⁷⁷Lu-lilotomab satetraxetan significantly increases the ratio of tumor to red marrow absorbed dose in non-Hodgkin lymphoma patients
Eur J Nucl Med Mol Imaging, 45 (7), 1233-1241
DOI 10.1007/s00259-018-3964-9, PubMed 29470615

van Rhee F, Voorhees P, Dispenzieri A, Fosså A, Srkalovic G, Ide M, Munshi N, Schey S, Streetly M, Pierson SK, Partridge HL, Mukherjee S, Shilling D, Stone K, Greenway A, Ruth J, Lechowicz MJ, Chandrakasan S, Jayanthan R, Jaffe ES, Leitch H, Pemmaraju N, Chadburn A, Lim MS, Elenitoba-Johnson KS et al. (2018)
International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease
Blood, 132 (20), 2115-2124
DOI 10.1182/blood-2018-07-862334, PubMed 30181172

Vodák D, Lorenz S, Nakken S, Aasheim LB, Holte H, Bai B, Myklebost O, Meza-Zepeda LA, Hovig E (2018)
Sample-Index Misassignment Impacts Tumour Exome Sequencing
Sci Rep, 8 (1), 5307
DOI 10.1038/s41598-018-23563-4, PubMed 29593270

Publications 2017

Barzenje DA, Kolstad A, Ghanima W, Holte H (2017)
Long-term outcome of patients with solitary plasmacytoma treated with radiotherapy: A population-based, single-center study with median follow-up of 13.7 years
Hematol Oncol, 36 (1), 217-223
DOI 10.1002/hon.2415, PubMed 28393375

Blakkisrud J, Holtedahl JE, Løndalen A, Dahle J, Bach-Gansmo T, Holte H, Nygaard S, Kolstad A, Stokke C (2017)
Biodistribution and Dosimetry Results from a Phase 1 Trial of Therapy with the Antibody-Radionuclide Conjugate ¹⁷⁷Lu-Lilotomab Satetraxetan
J Nucl Med, 59 (4), 704-710
DOI 10.2967/jnumed.117.195347, PubMed 28848035

Eskelund CW, Dahl C, Hansen JW, Westman M, Kolstad A, Pedersen LB, Montano-Almendras CP, Husby S, Freiburghaus C, Ek S, Pedersen A, Niemann C, Räty R, Brown P, Geisler CH, Andersen MK, Guldberg P, Jerkeman M, Grønbæk K (2017)
TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy
Blood, 130 (17), 1903-1910
DOI 10.1182/blood-2017-04-779736, PubMed 28819011

Fajgenbaum DC, Uldrick TS, Bagg A, Frank D, Wu D, Srkalovic G, Simpson D, Liu AY, Menke D, Chandrakasan S, Lechowicz MJ, Wong RS, Pierson S, Paessler M, Rossi JF, Ide M, Ruth J, Croglio M, Suarez A, Krymskaya V, Chadburn A, Colleoni G, Nasta S, Jayanthan R, Nabel CS et al. (2017)
International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease
Blood, 129 (12), 1646-1657
DOI 10.1182/blood-2016-10-746933, PubMed 28087540

Josefsson SE, Huse K, Kolstad A, Beiske K, Pende D, Steen CB, Inderberg EM, Lingjærde OC, Østenstad B, Smeland EB, Levy R, Irish JM, Myklebust JH (2017)
T Cells Expressing Checkpoint Receptor TIGIT Are Enriched in Follicular Lymphoma Tumors and Characterized by Reversible Suppression of T-cell Receptor Signaling
Clin Cancer Res, 24 (4), 870-881
DOI 10.1158/1078-0432.CCR-17-2337, PubMed 29217528

Leivonen SK, Icay K, Jäntti K, Siren I, Liu C, Alkodsi A, Cervera A, Ludvigsen M, Hamilton-Dutoit SJ, d'Amore F, Karjalainen-Lindsberg ML, Delabie J, Holte H, Lehtonen R, Hautaniemi S, Leppä S (2017)
MicroRNAs regulate key cell survival pathways and mediate chemosensitivity during progression of diffuse large B-cell lymphoma
Blood Cancer J, 7 (12), 654
DOI 10.1038/s41408-017-0033-8, PubMed 29242506

Leivonen SK, Taskinen M, Cervera A, Karjalainen-Lindsberg ML, Delabie J, Holte H, Lehtonen R, Hautaniemi S, Leppä S (2017)
Alternative splicing discriminates molecular subtypes and has prognostic impact in diffuse large B-cell lymphoma
Blood Cancer J, 7 (8), e596
DOI 10.1038/bcj.2017.71, PubMed 28841210

Meriranta L, Pasanen A, Louhimo R, Cervera A, Alkodsi A, Autio M, Taskinen M, Rantanen V, Karjalainen-Lindsberg ML, Holte H, Delabie J, Lehtonen R, Hautaniemi S, Leppä S (2017)
Deltex-1 mutations predict poor survival in diffuse large B-cell lymphoma
Haematologica, 102 (5), e195-e198
DOI 10.3324/haematol.2016.157495, PubMed 28183850

Scott DW, Abrisqueta P, Wright GW, Slack GW, Mottok A, Villa D, Jares P, Rauert-Wunderlich H, Royo C, Clot G, Pinyol M, Boyle M, Chan FC, Braziel RM, Chan WC, Weisenburger DD, Cook JR, Greiner TC, Fu K, Ott G, Delabie J, Smeland EB, Holte H, Jaffe ES, Steidl C et al. (2017)
New Molecular Assay for the Proliferation Signature in Mantle Cell Lymphoma Applicable to Formalin-Fixed Paraffin-Embedded Biopsies
J Clin Oncol, 35 (15), 1668-1677
DOI 10.1200/JCO.2016.70.7901, PubMed 28291392

Seland M, Smeland KB, Bjøro T, Falk RS, Fosså SD, Gjesdal CG, Godang K, Holte H, Svartberg J, Syversen U, Bollerslev J, Kiserud CE (2017)
Bone mineral density is close to normal for age in long-term lymphoma survivors treated with high-dose therapy with autologous stem cell transplantation
Acta Oncol, 56 (4), 590-598
DOI 10.1080/0284186X.2016.1267870, PubMed 28077016

Stenehjem JS, Smeland KB, Murbraech K, Holte H, Kvaløy SO, Wethal T, Kiserud CE, Samersaw-Lund MB (2017)
Obstructive and restrictive pulmonary dysfunction in long-term lymphoma survivors after high-dose therapy with autologous stem cell transplantation
Acta Oncol, 57 (6), 773-781
DOI 10.1080/0284186X.2017.1406137, PubMed 29171324

Vandraas KF, Torfoss D, Berstad AE, Horndalsveen H, Turowski G (2017)
Cancer patient in the 50s with troublesome palpitations
Tidsskr. Nor. Laegeforen., 137 (16), 1210-1213

Wogsland CE, Greenplate AR, Kolstad A, Myklebust JH, Irish JM, Huse K (2017)
Mass Cytometry of Follicular Lymphoma Tumors Reveals Intrinsic Heterogeneity in Proteins Including HLA-DR and a Deficit in Nonmalignant Plasmablast and Germinal Center B-Cell Populations
Cytometry B Clin Cytom, 92 (1), 79-87
DOI 10.1002/cyto.b.21498, PubMed 27933753

Publications 2016

Albertsson-Lindblad A, Kolstad A, Laurell A, Räty R, Grønbæk K, Sundberg J, Pedersen LB, Ralfkiær E, Karjalainen-Lindsberg ML, Sundström C, Ehinger M, Geisler C, Jerkeman M (2016)
Lenalidomide-bendamustine-rituximab in patients older than 65 years with untreated mantle cell lymphoma
Blood, 128 (14), 1814-1820
DOI 10.1182/blood-2016-03-704023, PubMed 27354719

Barrington SF, Kirkwood AA, Franceschetto A, Fulham MJ, Roberts TH, Almquist H, Brun E, Hjorthaug K, Viney ZN, Pike LC, Federico M, Luminari S, Radford J, Trotman J, Fosså A, Berkahn L, Molin D, D'Amore F, Sinclair DA, Smith P, O'Doherty MJ, Stevens L, Johnson PW (2016)
PET-CT for staging and early response: results from the Response-Adapted Therapy in Advanced Hodgkin Lymphoma study
Blood, 127 (12), 1531-8
DOI 10.1182/blood-2015-11-679407, PubMed 26747247

Barzenje DA, Holte H, Fosså A, Ghanima W, Liestøl K, Delabie J, Kolstad A (2016)
Long-term outcome for patients with early stage marginal zone lymphoma and mantle cell lymphoma
Leuk Lymphoma, 58 (3), 623-632
DOI 10.1080/10428194.2016.1204653, PubMed 27389974

Blaker YN, Spetalen S, Brodtkorb M, Lingjaerde OC, Beiske K, Østenstad B, Sander B, Wahlin BE, Melen CM, Myklebust JH, Holte H, Delabie J, Smeland EB (2016)
The tumour microenvironment influences survival and time to transformation in follicular lymphoma in the rituximab era
Br J Haematol, 175 (1), 102-14
DOI 10.1111/bjh.14201, PubMed 27341313

Blakkisrud J, Løndalen A, Dahle J, Turner S, Holte H, Kolstad A, Stokke C (2016)
Red Marrow-Absorbed Dose for Non-Hodgkin Lymphoma Patients Treated with 177Lu-Lilotomab Satetraxetan, a Novel Anti-CD37 Antibody-Radionuclide Conjugate
J Nucl Med, 58 (1), 55-61
DOI 10.2967/jnumed.116.180471, PubMed 27587710

Blakkisrud J, Løndalen A, Martinsen AC, Dahle J, Holtedahl JE, Bach-Gansmo T, Holte H, Kolstad A, Stokke C (2016)
Tumor-Absorbed Dose for Non-Hodgkin Lymphoma Patients Treated with the Anti-CD37 Antibody Radionuclide Conjugate 177Lu-Lilotomab Satetraxetan
J Nucl Med, 58 (1), 48-54
DOI 10.2967/jnumed.116.173922, PubMed 27493270

Coiffier B, Thieblemont C, de Guibert S, Dupuis J, Ribrag V, Bouabdallah R, Morschhauser F, Navarro R, Le Gouill S, Haioun C, Houot R, Casasnovas O, Holte H, Lamy T, Broussais F, Payrard S, Hatteville L, Tilly H (2016)
A phase II, single-arm, multicentre study of coltuximab ravtansine (SAR3419) and rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma
Br J Haematol, 173 (5), 722-30
DOI 10.1111/bjh.13992, PubMed 27010483

Eskelund CW, Kolstad A, Jerkeman M, Räty R, Laurell A, Eloranta S, Smedby KE, Husby S, Pedersen LB, Andersen NS, Eriksson M, Kimby E, Bentzen H, Kuittinen O, Lauritzsen GF, Nilsson-Ehle H, Ralfkiaer E, Ehinger M, Sundström C, Delabie J, Karjalainen-Lindsberg ML, Workman CT, Garde C, Elonen E, Brown P et al. (2016)
15-year follow-up of the Second Nordic Mantle Cell Lymphoma trial (MCL2): prolonged remissions without survival plateau
Br J Haematol, 175 (3), 410-418
DOI 10.1111/bjh.14241, PubMed 27378674

Fluge Ø, Mella O, Bruland O, Risa K, Dyrstad SE, Alme K, Rekeland IG, Sapkota D, Røsland GV, Fosså A, Ktoridou-Valen I, Lunde S, Sørland K, Lien K, Herder I, Thürmer H, Gotaas ME, Baranowska KA, Bohnen LM, Schäfer C, McCann A, Sommerfelt K, Helgeland L, Ueland PM, Dahl O et al. (2016)
Metabolic profiling indicates impaired pyruvate dehydrogenase function in myalgic encephalopathy/chronic fatigue syndrome
JCI Insight, 1 (21), e89376
DOI 10.1172/jci.insight.89376, PubMed 28018972

Holm KL, Indrevaer RL, Myklebust JH, Kolstad A, Moskaug JØ, Naderi EH, Blomhoff HK (2016)
Myeloid cell leukaemia 1 has a vital role in retinoic acid-mediated protection of Toll-like receptor 9-stimulated B cells from spontaneous and DNA damage-induced apoptosis
Immunology, 149 (1), 62-73
DOI 10.1111/imm.12629, PubMed 27278254

Johnson P, Federico M, Kirkwood A, Fosså A, Berkahn L, Carella A, d'Amore F, Enblad G, Franceschetto A, Fulham M, Luminari S, O'Doherty M, Patrick P, Roberts T, Sidra G, Stevens L, Smith P, Trotman J, Viney Z, Radford J, Barrington S (2016)
Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin's Lymphoma
N Engl J Med, 374 (25), 2419-29
DOI 10.1056/NEJMoa1510093, PubMed 27332902

Kiserud CE, Fagerli UM, Smeland KB, Fluge Ø, Bersvendsen H, Kvaløy S, Holte H, Dahl AA (2016)
Pattern of employment and associated factors in long-term lymphoma survivors 10 years after high-dose chemotherapy with autologous stem cell transplantation
Acta Oncol, 55 (5), 547-53
DOI 10.3109/0284186X.2015.1125015, PubMed 27123741

Kolstad A, Pedersen LB, Eskelund CW, Husby S, Grønbæk K, Jerkeman M, Laurell A, Räty R, Elonen E, Andersen NS, Brown PD, Kimby E, Bentzen H, Sundström C, Ehinger M, Karjalainen-Lindsberg ML, Delabie J, Ralfkiær E, Fagerli UM, Nilsson-Ehle H, Lauritzsen GF, Kuittinen O, Niemann C, Geisler CH, Nordic Lymphoma Group (2016)
Molecular Monitoring after Autologous Stem Cell Transplantation and Preemptive Rituximab Treatment of Molecular Relapse; Results from the Nordic Mantle Cell Lymphoma Studies (MCL2 and MCL3) with Median Follow-Up of 8.5 Years
Biol Blood Marrow Transplant, 23 (3), 428-435
DOI 10.1016/j.bbmt.2016.12.634, PubMed 28039078

Marques A, Rodrigues AM, Romeu JC, Ruano A, Barbosa AP, Simões E, Águas F, Canhão H, Alves JD, Lucas R, Branco JC, Laíns J, Mascarenhas M, Simões S, Tavares V, Lourenço O, da Silva JA (2016)
Multidisciplinary Portuguese recommendations on DXA request and indication to treat in the prevention of fragility fractures
Acta Reumatol Port, 41 (4), 305-321
PubMed 27750276

Mensali N, Ying F, Sheng VO, Yang W, Walseng E, Kumari S, Fallang LE, Kolstad A, Uckert W, Malmberg KJ, Wälchli S, Olweus J (2016)
Targeting B-cell neoplasia with T-cell receptors recognizing a CD20-derived peptide on patient-specific HLA
Oncoimmunology, 5 (5), e1138199
DOI 10.1080/2162402X.2016.1138199, PubMed 27467957

Murbraech K, Holte E, Broch K, Smeland KB, Holte H, Rösner A, Lund MB, Dalen H, Kiserud C, Aakhus S (2016)
Impaired Right Ventricular Function in Long-Term Lymphoma Survivors
J Am Soc Echocardiogr, 29 (6), 528-36
DOI 10.1016/j.echo.2016.02.014, PubMed 27038515

Murbraech K, Wethal T, Smeland KB, Holte H, Loge JH, Holte E, Rösner A, Dalen H, Kiserud CE, Aakhus S (2016)
Valvular Dysfunction in Lymphoma Survivors Treated With Autologous Stem Cell Transplantation: A National Cross-Sectional Study
JACC Cardiovasc Imaging, 9 (3), 230-9
DOI 10.1016/j.jcmg.2015.06.028, PubMed 26897666

Pauly F, Fjordén K, Leppä S, Holte H, Björkholm M, Fluge Ø, Møller Pedersen L, Eriksson M, Isinger-Ekstrand A, Borrebaeck CA, Jerkeman M, Wingren C (2016)
Plasma immunoprofiling of patients with high-risk diffuse large B-cell lymphoma: a Nordic Lymphoma Group study
Blood Cancer J, 6 (11), e501
DOI 10.1038/bcj.2016.113, PubMed 27858932

Smeland KB, Kiserud CE, Lauritzsen GF, Blystad AK, Fagerli UM, Falk RS, Fluge Ø, Fosså A, Kolstad A, Loge JH, Maisenhölder M, Østenstad B, Kvaløy S, Holte H (2016)
A national study on conditional survival, excess mortality and second cancer after high dose therapy with autologous stem cell transplantation for non-Hodgkin lymphoma
Br J Haematol, 173 (3), 432-43
DOI 10.1111/bjh.13965, PubMed 26914167

Stenehjem JS, Smeland KB, Murbraech K, Holte H, Kvaløy S, Thorsen L, Arbo I, Jones LW, Aakhus S, Lund MB, Kiserud CE (2016)
Cardiorespiratory fitness in long-term lymphoma survivors after high-dose chemotherapy with autologous stem cell transplantation
Br J Cancer, 115 (2), 178-87
DOI 10.1038/bjc.2016.180, PubMed 27351215

Torfoss D (2016)
Carbapenems and febrile neutropenia - author's reply
Clin Microbiol Infect, 23 (3), 214
DOI 10.1016/j.cmi.2016.12.019, PubMed 28025133

Torfoss D, Fladhagen T, Holte H, Brinch L, Schjesvold FH, Fløisand Y, Nyquist E, Dalgaard J, Meyer P, Lehmann AK, Hammerstrøm J, Skjelbakken T, Høiby EA, Sandvik L, Kvaløy S (2016)
Benzylpenicillin plus an aminoglycoside versus meropenem in neutropenic lymphoma and leukaemia patients with a suspected bacterial infection: a randomized, controlled trial
Clin Microbiol Infect, 23 (3), 179-187
DOI 10.1016/j.cmi.2016.10.019, PubMed 27793737

Publications 2015

Barzenje DA, Cvancarova Småstuen M, Liestøl K, Fosså A, Delabie J, Kolstad A, Holte H (2015)
Radiotherapy Compared to Other Strategies in the Treatment of Stage I/II Follicular Lymphoma: A Study of 404 Patients with a Median Follow-Up of 15 Years
PLoS One, 10 (7), e0131158
DOI 10.1371/journal.pone.0131158, PubMed 26147646

Blaker YN, Brodtkorb M, Maddison J, Hveem TS, Nesheim JA, Mohn HM, Kolstad A, Geisler CH, Liestøl K, Smeland EB, Holte H, Delabie J, Danielsen H (2015)
Computerized image analysis of the Ki-67 proliferation index in mantle cell lymphoma
Histopathology, 67 (1), 62-9
DOI 10.1111/his.12624, PubMed 25431344

Blix ES, Kildal AB, Bertelsen E, Waage A, Myklebust JH, Kolstad A, Husebekk A (2015)
Content of endothelial progenitor cells in autologous stem cell grafts predict survival after transplantation for multiple myeloma
Biol Blood Marrow Transplant, 21 (5), 840-7
DOI 10.1016/j.bbmt.2014.12.027, PubMed 25689789

Brabrand S, Johannessen B, Axcrona U, Kraggerud SM, Berg KG, Bakken AC, Bruun J, Fosså SD, Lothe RA, Lehne G, Skotheim RI (2015)
Exome sequencing of bilateral testicular germ cell tumors suggests independent development lineages
Neoplasia, 17 (2), 167-74
DOI 10.1016/j.neo.2014.12.005, PubMed 25748235

Gouveia N, Rodrigues AM, Ramiro S, Machado P, da Costa LP, Mourão AF, Silva I, Rego T, Laires P, André R, Mauricio L, Romeu JC, Tavares V, Cerol J, Canhão H, Branco JC (2015)
EpiReumaPt: how to perform a national population based study - a practical guide
Acta Reumatol Port, 40 (2), 128-36
PubMed 26219966

Hoster E, Geisler CH, Doorduijn J, van der Holt B, Walewski J, Bloehdorn J, Ribrag V, Salles G, Hallek M, Pott C, Szymczyk M, Kolstad A, Laurell A, Räty R, Jerkeman M, Van't Veer M, Kluin-Nelemans JC, Klapper W, Unterhalt M, Dreyling M, Hermine O (2015)
Total body irradiation after high-dose cytarabine in mantle cell lymphoma: a comparison of Nordic MCL2, HOVON-45, and European MCL Younger trials
Leukemia, 30 (6), 1428-30
DOI 10.1038/leu.2015.322, PubMed 26598017

Kasenda B, Ferreri AJ, Marturano E, Forst D, Bromberg J, Ghesquieres H, Ferlay C, Blay JY, Hoang-Xuan K, Pulczynski EJ, Fosså A, Okoshi Y, Chiba S, Fritsch K, Omuro A, O'Neill BP, Bairey O, Schandelmaier S, Gloy V, Bhatnagar N, Haug S, Rahner S, Batchelor TT, Illerhaus G, Briel M (2015)
First-line treatment and outcome of elderly patients with primary central nervous system lymphoma (PCNSL)--a systematic review and individual patient data meta-analysis
Ann Oncol, 26 (7), 1305-13
DOI 10.1093/annonc/mdv076, PubMed 25701456

Kimby E, Östenstad B, Brown P, Hagberg H, Erlanson M, Holte H, Linden O, Johansson AS, Ahlgren T, Wader K, Wahlin BE, Delabie J, Sundström C, Nordic Lymphoma Group (NLG) (2015)
Two courses of four weekly infusions of rituximab with or without interferon-α2a: final results from a randomized phase III study in symptomatic indolent B-cell lymphomas
Leuk Lymphoma, 56 (9), 2598-607
DOI 10.3109/10428194.2015.1014363, PubMed 25686644

Knappskog S, Berge EO, Chrisanthar R, Geisler S, Staalesen V, Leirvaag B, Yndestad S, de Faveri E, Karlsen BO, Wedge DC, Akslen LA, Lilleng PK, Løkkevik E, Lundgren S, Østenstad B, Risberg T, Mjaaland I, Aas T, Lønning PE (2015)
Concomitant inactivation of the p53- and pRB- functional pathways predicts resistance to DNA damaging drugs in breast cancer in vivo
Mol Oncol, 9 (8), 1553-64
DOI 10.1016/j.molonc.2015.04.008, PubMed 26004085

Kolstad A, Olweus J (2015)
"In situ" vaccination for systemic effects in follicular lymphoma
Oncoimmunology, 4 (7), e1014773
DOI 10.1080/2162402X.2015.1014773, PubMed 26140239

Malecka A, Tierens A, Østlie I, Schmitz R, Trøen G, Spetalen S, Staudt LM, Smeland E, Holte H, Delabie J (2015)
Primary diffuse large B-cell lymphoma associated with clonally-related monoclonal B lymphocytosis indicates a common precursor cell
Haematologica, 100 (10), e415-8
DOI 10.3324/haematol.2015.126656, PubMed 26001788

Murbraech K, Smeland KB, Holte H, Loge JH, Lund MB, Wethal T, Holte E, Rösner A, Dalen H, Kvaløy S, Falk RS, Aakhus S, Kiserud CE (2015)
Heart Failure and Asymptomatic Left Ventricular Systolic Dysfunction in Lymphoma Survivors Treated With Autologous Stem-Cell Transplantation: A National Cross-Sectional Study
J Clin Oncol, 33 (24), 2683-91
DOI 10.1200/JCO.2015.60.8125, PubMed 26169610

Rodrigues AM, Gouveia N, da Costa LP, Eusébio M, Ramiro S, Machado P, Mourão AF, Silva I, Laires P, Sepriano A, Araújo F, Coelho PS, Gonçalves S, Zhao A, Fonseca JE, de Almeida JM, Tavares V, da Silva JA, Barros H, Cerol J, Mendes J, Carmona L, Canhão H, Branco JC (2015)
EpiReumaPt- the study of rheumatic and musculoskeletal diseases in Portugal: a detailed view of the methodology
Acta Reumatol Port, 40 (2), 110-24
PubMed 26219965

Seland M, Bjøro T, Furre T, Schreiner T, Bollerslev J, Fosså SD, Loge JH, Holte H, Kiserud CE (2015)
Hormonal dysfunction is frequent in cancer survivors treated with radiotherapy to the head and neck region
J Cancer Surviv, 9 (4), 630-40
DOI 10.1007/s11764-015-0439-x, PubMed 25750158

Smeland KB, Kiserud CE, Lauritzsen GF, Fagerli UM, Falk RS, Fluge Ø, Fosså A, Kolstad A, Loge JH, Maisenhölder M, Kvaløy S, Holte H (2015)
Conditional survival and excess mortality after high-dose therapy with autologous stem cell transplantation for adult refractory or relapsed Hodgkin lymphoma in Norway
Haematologica, 100 (6), e240-3
DOI 10.3324/haematol.2014.119214, PubMed 25682605

van Rhee F, Rothman M, Ho KF, Fleming S, Wong RS, Fosså A, Dispenzieri A, Cavet J, Munshi N, Vermeulen J, Casper C (2015)
Patient-reported Outcomes for Multicentric Castleman's Disease in a Randomized, Placebo-controlled Study of Siltuximab
Patient, 8 (2), 207-16
DOI 10.1007/s40271-015-0120-5, PubMed 25736164

Publications 2014

Bethge N, Honne H, Andresen K, Hilden V, Trøen G, Liestøl K, Holte H, Delabie J, Lind GE, Smeland EB (2014)
A gene panel, including LRP12, is frequently hypermethylated in major types of B-cell lymphoma
PLoS One, 9 (9), e104249
DOI 10.1371/journal.pone.0104249, PubMed 25226156

Blaker YN, Eide MB, Liestøl K, Lauritzsen GF, Kolstad A, Fosså A, Smeland EB, Holte H (2014)
High dose chemotherapy with autologous stem cell transplant for patients with transformed B-cell non-Hodgkin lymphoma in the rituximab era
Leuk Lymphoma, 55 (10), 2319-27
DOI 10.3109/10428194.2013.871632, PubMed 24432894

Fiskvik I, Beiske K, Delabie J, Yri O, Spetalen S, Karjalainen-Lindsberg ML, Leppä S, Liestøl K, Smeland EB, Holte H (2014)
Combining MYC, BCL2 and TP53 gene and protein expression alterations improves risk stratification in diffuse large B-cell lymphoma
Leuk Lymphoma, 56 (6), 1742-9
DOI 10.3109/10428194.2014.970550, PubMed 25284491

Hagtvedt T, Seierstad T, Lund KV, Løndalen AM, Bogsrud TV, Smith HJ, Geier OM, Holte H, Aaløkken TM (2014)
Diffusion-weighted MRI compared to FDG PET/CT for assessment of early treatment response in lymphoma
Acta Radiol, 56 (2), 152-8
DOI 10.1177/0284185114526087, PubMed 24585944

Hasenclever D, Kurch L, Mauz-Körholz C, Elsner A, Georgi T, Wallace H, Landman-Parker J, Moryl-Bujakowska A, Cepelová M, Karlén J, Álvarez Fernández-Teijeiro A, Attarbaschi A, Fosså A, Pears J, Hraskova A, Bergsträsser E, Beishuizen A, Uyttebroeck A, Schomerus E, Sabri O, Körholz D, Kluge R (2014)
qPET - a quantitative extension of the Deauville scale to assess response in interim FDG-PET scans in lymphoma
Eur J Nucl Med Mol Imaging, 41 (7), 1301-8
DOI 10.1007/s00259-014-2715-9, PubMed 24604592

Husøy MA, Brinch L, Tjønnfjord GE, Gedde-Dahl T, Heldal D, Holme PA, Dybedal I, Kolstad A, Akkök ÇA, Rollag H, Gaustad P, Bergan S, Egeland T, Josefsen D, Kvalheim G, Fløisand Y (2014)
[Allogeneic stem-cell transplantation in adults 1985-2012: results and development]
Tidsskr Nor Laegeforen, 134 (16), 1569-75
DOI 10.4045/tidsskr.13.1415, PubMed 25178233

Kiserud CE, Seland M, Holte H, Fosså A, Fosså SD, Bollerslev J, Bjøro T, Loge JH (2014)
Fatigue in male lymphoma survivors differs between diagnostic groups and is associated with latent hypothyroidism
Acta Oncol, 54 (1), 49-59
DOI 10.3109/0284186X.2014.948057, PubMed 25140862

Kolstad A, Kumari S, Walczak M, Madsbu U, Hagtvedt T, Bogsrud TV, Kvalheim G, Holte H, Aurlien E, Delabie J, Tierens A, Olweus J (2014)
Sequential intranodal immunotherapy induces antitumor immunity and correlated regression of disseminated follicular lymphoma
Blood, 125 (1), 82-9
DOI 10.1182/blood-2014-07-592162, PubMed 25293773

Kolstad A, Laurell A, Jerkeman M, Grønbæk K, Elonen E, Räty R, Pedersen LB, Loft A, Bogsrud TV, Kimby E, Hansen PB, Fagerli UM, Nilsson-Ehle H, Lauritzsen GF, Lehmann AK, Sundstrom C, Karjalainen-Lindsberg ML, Ralfkiaer E, Ehinger M, Delabie J, Bentzen H, Schildt J, Kostova-Aherdan K, Frederiksen H, Brown Pde N et al. (2014)
Nordic MCL3 study: 90Y-ibritumomab-tiuxetan added to BEAM/C in non-CR patients before transplant in mantle cell lymphoma
Blood, 123 (19), 2953-9
DOI 10.1182/blood-2013-12-541953, PubMed 24652994

Mylam KJ, Kostakoglu L, Hutchings M, Coleman M, Lamonica D, Czuczman MS, Diehl LF, Nielsen AL, Jensen P, Loft A, Hendel HW, Iyer V, Leppä S, Jyrkkiö S, Holte H, Eriksson M, Gillstrøm D, Hansen PB, Seppänen M, Hjorthaug K, Brown Pde N, Pedersen LM (2014)
(18)F-fluorodeoxyglucose-positron emission tomography/computed tomography after one cycle of chemotherapy in patients with diffuse large B-cell lymphoma: results of a Nordic/US intergroup study
Leuk Lymphoma, 56 (7), 2005-12
DOI 10.3109/10428194.2014.975800, PubMed 25330442

Nordström L, Sernbo S, Eden P, Grønbaek K, Kolstad A, Räty R, Karjalainen ML, Geisler C, Ralfkiaer E, Sundström C, Laurell A, Delabie J, Ehinger M, Jerkeman M, Ek S (2014)
SOX11 and TP53 add prognostic information to MIPI in a homogenously treated cohort of mantle cell lymphoma--a Nordic Lymphoma Group study
Br J Haematol, 166 (1), 98-108
DOI 10.1111/bjh.12854, PubMed 24684350

Pulczynski EJ, Kuittinen O, Erlanson M, Hagberg H, Fosså A, Eriksson M, Nordstrøm M, Østenstad B, Fluge Ø, Leppä S, Fiirgaard B, Bersvendsen H, Fagerli UM (2014)
Successful change of treatment strategy in elderly patients with primary central nervous system lymphoma by de-escalating induction and introducing temozolomide maintenance: results from a phase II study by the Nordic Lymphoma Group
Haematologica, 100 (4), 534-40
DOI 10.3324/haematol.2014.108472, PubMed 25480497

Riihijärvi S, Fiskvik I, Taskinen M, Vajavaara H, Tikkala M, Yri O, Karjalainen-Lindsberg ML, Delabie J, Smeland E, Holte H, Leppä S (2014)
Prognostic influence of macrophages in patients with diffuse large B-cell lymphoma: a correlative study from a Nordic phase II trial
Haematologica, 100 (2), 238-45
DOI 10.3324/haematol.2014.113472, PubMed 25381134

Rodrigues AM, de Freitas CH, Guerreiro Md, Jorge MS (2014)
[Preceptorship in the perspective of comprehensive care: conversations with nurses]
Rev Gaucha Enferm, 35 (2), 106-12
DOI 10.1590/1983-1447.2014.02.43946, PubMed 25158469

Taskinen M, Louhimo R, Koivula S, Chen P, Rantanen V, Holte H, Delabie J, Karjalainen-Lindsberg ML, Björkholm M, Fluge Ø, Pedersen LM, Fjordén K, Jerkeman M, Eriksson M, Hautaniemi S, Leppä S (2014)
Deregulation of COMMD1 is associated with poor prognosis in diffuse large B-cell lymphoma
PLoS One, 9 (3), e91031
DOI 10.1371/journal.pone.0091031, PubMed 24625556

van Rhee F, Wong RS, Munshi N, Rossi JF, Ke XY, Fosså A, Simpson D, Capra M, Liu T, Hsieh RK, Goh YT, Zhu J, Cho SG, Ren H, Cavet J, Bandekar R, Rothman M, Puchalski TA, Reddy M, van de Velde H, Vermeulen J, Casper C (2014)
Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial
Lancet Oncol, 15 (9), 966-74
DOI 10.1016/S1470-2045(14)70319-5, PubMed 25042199

Publications 2013

Bersvendsen H, Kolstad A, Blystad AK, Aurlien E, Fosså A, Kvaløy SO, Holte H, Lauritzsen GF (2013)
Multimodal treatment with ALL-like chemotherapy, Auto-SCT and radiotherapy for lymphoblastic lymphoma
Acta Oncol, 53 (5), 680-7
DOI 10.3109/0284186X.2013.855816, PubMed 24237392

Bethge N, Honne H, Hilden V, Trøen G, Eknæs M, Liestøl K, Holte H, Delabie J, Smeland EB, Lind GE (2013)
Identification of highly methylated genes across various types of B-cell non-hodgkin lymphoma
PLoS One, 8 (11), e79602
DOI 10.1371/journal.pone.0079602, PubMed 24260260

Bethge N, Lothe RA, Honne H, Andresen K, Trøen G, Eknæs M, Liestøl K, Holte H, Delabie J, Smeland EB, Lind GE (2013)
Colorectal cancer DNA methylation marker panel validated with high performance in Non-Hodgkin lymphoma
Epigenetics, 9 (3), 428-36
DOI 10.4161/epi.27554, PubMed 24362313

Bosly A, Grigg A, Holte H, Gisselbrecht C, Radford J, Rossi A, Lopez-Guillermo A, Trneny M, Sebban C, Hagberg H, Leal da Costa F, Colombat P, Bron D, Coiffier B (2013)
A randomized study of interferon α-2b versus no treatment as consolidation after high dose therapy and autologous stem cell transplantation for patients with relapsed lymphoma
Oncologist, 18 (11), 1189
DOI 10.1634/theoncologist.2013-0223, PubMed 24105750

Brodtkorb M, Lingjærde OC, Huse K, Trøen G, Hystad M, Hilden VI, Myklebust JH, Leich E, Rosenwald A, Delabie J, Holte H, Smeland EB (2013)
Whole-genome integrative analysis reveals expression signatures predicting transformation in follicular lymphoma
Blood, 123 (7), 1051-4
DOI 10.1182/blood-2013-07-512392, PubMed 24357726

Dörffel W, Rühl U, Lüders H, Claviez A, Albrecht M, Bökkerink J, Holte H, Karlen J, Mann G, Marciniak H, Niggli F, Schmiegelow K, Schwarze EW, Pötter R, Wickmann L, Schellong G (2013)
Treatment of children and adolescents with Hodgkin lymphoma without radiotherapy for patients in complete remission after chemotherapy: final results of the multinational trial GPOH-HD95
J Clin Oncol, 31 (12), 1562-8
DOI 10.1200/JCO.2012.45.3266, PubMed 23509321

Fiskvik I, Aamot HV, Delabie J, Smeland EB, Stokke T, Heim S, Holte H (2013)
Karyotyping of diffuse large B-cell lymphomas: loss of 17p is associated with poor patient outcome
Eur J Haematol, 91 (4), 332-8
DOI 10.1111/ejh.12171, PubMed 23859481

Fosså A, Røsok BI, Kazaryan AM, Holte HJ, Brennhovd B, Westerheim O, Marangos IP, Edwin B (2013)
Laparoscopic versus open surgery in stage I-III adrenocortical carcinoma -- a retrospective comparison of 32 patients
Acta Oncol, 52 (8), 1771-7
DOI 10.3109/0284186X.2013.765065, PubMed 23398621

Gonçalves MJ, Rodrigues AM, Canhão H, Fonseca JE (2013)
Osteoporosis: from bone biology to individual treatment decision
Acta Med Port, 26 (4), 445-55
PubMed 24016655

Hagtvedt T, Aaløkken TM, Smith HJ, Graff BA, Holte H, Kolbenstvedt A (2013)
Enhancement characteristics of retroperitoneal lymphomatous lymph nodes
Acta Radiol, 54 (3), 333-9
DOI 10.1258/ar.2012.120679, PubMed 23446747

Haug JB, Berild D, Blomberg B, Bruun JN, Flaatten HK, Leiva RA, Skrede S, Torfoss D, Undseth Ø (2013)
[Aminoglycosides in severe sepsis]
Tidsskr Nor Laegeforen, 133 (15), 1553-4
DOI 10.4045/tidsskr.13.0866, PubMed 23970249

Laurell A, Kolstad A, Jerkeman M, Räty R, Geisler CH (2013)
High dose cytarabine with rituximab is not enough in first-line treatment of mantle cell lymphoma with high proliferation: early closure of the Nordic Lymphoma Group Mantle Cell Lymphoma 5 trial
Leuk Lymphoma, 55 (5), 1206-8
DOI 10.3109/10428194.2013.825906, PubMed 23876100

Martins P, Cleary DF, Pires AC, Rodrigues AM, Quintino V, Calado R, Gomes NC (2013)
Molecular analysis of bacterial communities and detection of potential pathogens in a recirculating aquaculture system for Scophthalmus maximus and Solea senegalensis
PLoS One, 8 (11), e80847
DOI 10.1371/journal.pone.0080847, PubMed 24278329

Moura RA, Canhão H, Polido-Pereira J, Rodrigues AM, Navalho M, Mourão AF, Resende C, Campanilho-Marques R, Madruga Dias J, da Silva JA, Graca L, Fonseca JE (2013)
BAFF and TACI gene expression are increased in patients with untreated very early rheumatoid arthritis
J Rheumatol, 40 (8), 1293-302
DOI 10.3899/jrheum.121110, PubMed 23772083

Myklebust JH, Irish JM, Brody J, Czerwinski DK, Houot R, Kohrt HE, Timmerman J, Said J, Green MR, Delabie J, Kolstad A, Alizadeh AA, Levy R (2013)
High PD-1 expression and suppressed cytokine signaling distinguish T cells infiltrating follicular lymphoma tumors from peripheral T cells
Blood, 121 (8), 1367-76
DOI 10.1182/blood-2012-04-421826, PubMed 23297127

Navalho M, Resende C, Rodrigues AM, Pereira da Silva JA, Fonseca JE, Campos J, Canhão H (2013)
Bilateral evaluation of the hand and wrist in untreated early inflammatory arthritis: a comparative study of ultrasonography and magnetic resonance imaging
J Rheumatol, 40 (8), 1282-92
DOI 10.3899/jrheum.120713, PubMed 23729806

Smeland KB, Kiserud CE, Lauritzsen GF, Blystad AK, Fagerli UM, Fluge Ø, Fosså A, Hammerstrøm J, Kolstad A, Loge JH, Maisenhølder M, Østenstad B, Kvaløy S, Holte H (2013)
High-dose therapy with autologous stem cell support for lymphoma in Norway 1987-2008
Tidsskr Nor Laegeforen, 133 (16), 1704-9
DOI 10.4045/tidsskr.13.0243, PubMed 24005706

Tjessem KH, Johansen S, Malinen E, Reinertsen KV, Danielsen T, Fosså SD, Fosså A (2013)
Long-term cardiac mortality after hypofractionated radiation therapy in breast cancer
Int J Radiat Oncol Biol Phys, 87 (2), 337-43
DOI 10.1016/j.ijrobp.2013.05.038, PubMed 23886416

Wahlin BE, Sundström C, Sander B, Christensson B, Jeppsson-Ahlberg Å, Hjalmarsson E, Holte H, Østenstad B, Brown PD, Smeland EB, Kimby E (2013)
Higher World Health Organization grades of follicular lymphoma correlate with better outcome in two Nordic Lymphoma Group trials of rituximab without chemotherapy
Leuk Lymphoma, 55 (2), 288-95
DOI 10.3109/10428194.2013.802778, PubMed 23662992

Wethal T, Nedregaard B, Andersen R, Fosså A, Lund MB, Günther A, Kvaløy S, Fosså SD, Kjekshus J (2013)
Atherosclerotic lesions in lymphoma survivors treated with radiotherapy
Radiother Oncol, 110 (3), 448-54
DOI 10.1016/j.radonc.2013.10.029, PubMed 24231235

Yri OE, Ekstrøm PO, Hilden V, Gaudernack G, Liestøl K, Smeland EB, Holte H (2013)
Influence of polymorphisms in genes encoding immunoregulatory proteins and metabolizing enzymes on susceptibility and outcome in patients with diffuse large B-cell lymphoma treated with rituximab
Leuk Lymphoma, 54 (10), 2205-14
DOI 10.3109/10428194.2013.774392, PubMed 23391141

Publications 2012

Blix ES, Irish JM, Husebekk A, Delabie J, Forfang L, Tierens AM, Myklebust JH, Kolstad A (2012)
Phospho-specific flow cytometry identifies aberrant signaling in indolent B-cell lymphoma
BMC Cancer, 12, 478
DOI 10.1186/1471-2407-12-478, PubMed 23072591

Blix ES, Irish JM, Husebekk A, Delabie J, Tierens AM, Myklebust JH, Kolstad A (2012)
Altered BCR and CD40 signalling are associated with clinical outcome in small lymphocytic lymphoma/chronic lymphocytic leukaemia and marginal zone lymphoma patients
Br J Haematol, 159 (5), 604-8
DOI 10.1111/bjh.12073, PubMed 23043253

Brabrand S, Fosså SD, Cvancarova M, Axcrona U, Lehne G (2012)
Probability of metachronous testicular cancer in patients with biopsy-proven intratubular germ cell neoplasia depends on first-time treatment of germ cell cancer
J Clin Oncol, 30 (32), 4004-10
DOI 10.1200/JCO.2011.40.8914, PubMed 23071246

Canhão H, Rodrigues AM, Mourão AF, Martins F, Santos MJ, Canas-Silva J, Polido-Pereira J, Pereira Silva JA, Costa JA, Araújo D, Silva C, Santos H, Duarte C, da Silva JA, Pimentel-Santos FM, Branco JC, Karlson EW, Fonseca JE, Solomon DH (2012)
Comparative effectiveness and predictors of response to tumour necrosis factor inhibitor therapies in rheumatoid arthritis
Rheumatology (Oxford), 51 (11), 2020-6
DOI 10.1093/rheumatology/kes184, PubMed 22843791

d'Amore F, Relander T, Lauritzsen GF, Jantunen E, Hagberg H, Anderson H, Holte H, Österborg A, Merup M, Brown P, Kuittinen O, Erlanson M, Østenstad B, Fagerli UM, Gadeberg OV, Sundström C, Delabie J, Ralfkiaer E, Vornanen M, Toldbod HE (2012)
Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01
J Clin Oncol, 30 (25), 3093-9
DOI 10.1200/JCO.2011.40.2719, PubMed 22851556

Fløisand Y, Brinch L, Gedde-Dahl T, Tjønnfjord GE, Dybedal I, Holte H, Heldal D, Torfoss D, Aurlien E, Lauritzsen GF, Fosså A, Lehne G, Baggerød E, Kvalheim G, Egeland T, Bishop MR, Fowler DH, Kolstad A (2012)
Ultra-short course sirolimus contributes to effective GVHD prophylaxis after reduced-intensity allogeneic hematopoietic cell transplantation
Bone Marrow Transplant, 47 (12), 1552-7
DOI 10.1038/bmt.2012.63, PubMed 22522568

Geisler CH, Kolstad A, Laurell A, Jerkeman M, Raty R, Andersen NS, Pedersen LB, Eriksson M, Nordstrom M, Kimby E, Bentzen H, Kuittinen O, Lauritzsen GF, Nilsson-Ehle H, Ralfkiaer E, Ehinger M, Sundstrom C, Delabie J, Karjalainen-Lindsberg ML, Brown P, Elonen E, Nordic Lymphoma Grp (2012)
Nordic MCL2 Trial Update: 6-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC Plus autologous stem-cell support: still very long survival but late relapses do occur (vol 158, pg 355, 2012)
Br. J. Haematol., 158 (6), 815-816
DOI 10.1111/bjh.12006

Geisler CH, Kolstad A, Laurell A, Jerkeman M, Räty R, Andersen NS, Pedersen LB, Eriksson M, Nordström M, Kimby E, Bentzen H, Kuittinen O, Lauritzsen GF, Nilsson-Ehle H, Ralfkiaer E, Ehinger M, Sundström C, Delabie J, Karjalainen-Lindsberg ML, Brown P, Elonen E, Nordic Lymphoma Group (2012)
Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem-cell support: still very long survival but late relapses do occur
Br J Haematol, 158 (3), 355-62
DOI 10.1111/j.1365-2141.2012.09174.x, PubMed 22640180

Holte H, Leppä S, Björkholm M, Fluge O, Jyrkkiö S, Delabie J, Sundström C, Karjalainen-Lindsberg ML, Erlanson M, Kolstad A, Fosså A, Ostenstad B, Löfvenberg E, Nordström M, Janes R, Pedersen LM, Anderson H, Jerkeman M, Eriksson M (2012)
Dose-densified chemoimmunotherapy followed by systemic central nervous system prophylaxis for younger high-risk diffuse large B-cell/follicular grade 3 lymphoma patients: results of a phase II Nordic Lymphoma Group study
Ann Oncol, 24 (5), 1385-92
DOI 10.1093/annonc/mds621, PubMed 23247661

Knappskog S, Chrisanthar R, Løkkevik E, Anker G, Østenstad B, Lundgren S, Risberg T, Mjaaland I, Leirvaag B, Miletic H, Lønning PE (2012)
Low expression levels of ATM may substitute for CHEK2 /TP53 mutations predicting resistance towards anthracycline and mitomycin chemotherapy in breast cancer
Breast Cancer Res, 14 (2), R47
DOI 10.1186/bcr3147, PubMed 22420423

Mathiesen RR, Borgen E, Renolen A, Løkkevik E, Nesland JM, Anker G, Ostenstad B, Lundgren S, Risberg T, Mjaaland I, Kvalheim G, Lønning PE, Naume B (2012)
Persistence of disseminated tumor cells after neoadjuvant treatment for locally advanced breast cancer predicts poor survival
Breast Cancer Res, 14 (4), R117
DOI 10.1186/bcr3242, PubMed 22889108

Mitrovic Z, Perry AM, Suzumiya J, Armitage JO, Au WY, Coiffier B, Holte H, Jaffe ES, Monserrat E, Rajan SK, Savage KJ, Tobinai K, Vose JM, Weisenburger DD (2012)
The prognostic significance of lymphopenia in peripheral T-cell and natural killer/T-cell lymphomas: a study of 826 cases from the International Peripheral T-cell Lymphoma Project
Am J Hematol, 87 (8), 790-4
DOI 10.1002/ajh.23205, PubMed 22488678

Navalho M, Resende C, Rodrigues AM, Ramos F, Gaspar A, Pereira da Silva JA, Fonseca JE, Campos J, Canhão H (2012)
Bilateral MR imaging of the hand and wrist in early and very early inflammatory arthritis: tenosynovitis is associated with progression to rheumatoid arthritis
Radiology, 264 (3), 823-33
DOI 10.1148/radiol.12112513, PubMed 22723498

Nyquist KB, Panagopoulos I, Thorsen J, Haugom L, Gorunova L, Bjerkehagen B, Fosså A, Guriby M, Nome T, Lothe RA, Skotheim RI, Heim S, Micci F (2012)
Whole-transcriptome sequencing identifies novel IRF2BP2-CDX1 fusion gene brought about by translocation t(1;5)(q42;q32) in mesenchymal chondrosarcoma
PLoS One, 7 (11), e49705
DOI 10.1371/journal.pone.0049705, PubMed 23185413

Olweus J, Kolstad A (2012)
[Can the immune system target cancer?]
Tidsskr Nor Laegeforen, 132 (7), 784-5
DOI 10.4045/tidsskr.12.0156, PubMed 22511078

Riihijärvi S, Nurmi H, Holte H, Björkholm M, Fluge O, Pedersen LM, Rydström K, Jerkeman M, Eriksson M, Leppä S (2012)
High serum vascular endothelial growth factor level is an adverse prognostic factor for high-risk diffuse large B-cell lymphoma patients treated with dose-dense chemoimmunotherapy
Eur J Haematol, 89 (5), 395-402
DOI 10.1111/ejh.12005, PubMed 22882209

Wahlin BE, Sander B, Christensson B, Ostenstad B, Holte H, Brown PD, Sundström C, Kimby E (2012)
Entourage: the immune microenvironment following follicular lymphoma
Blood Cancer J, 2 (1), e52
DOI 10.1038/bcj.2011.53, PubMed 22829236

Yri OE, Ekstrøm PO, Hilden V, Gaudernack G, Liestøl K, Smeland EB, Holte H (2012)
Polymorphisms in genes encoding interleukin-10 and drug metabolizing enzymes GSTP1, GSTT1, GSTA1 and UGT1A1 influence risk and outcome in Hodgkin lymphoma
Leuk Lymphoma, 53 (10), 1934-44
DOI 10.3109/10428194.2012.682307, PubMed 22475179

Publications 2011

Abrahamsen IW, Kjellevoll S, Greve-Isdahl M, Mensali N, Wälchli S, Kumari S, Loland BF, Egeland T, Kolstad A, Olweus J (2011)
T cells raised against allogeneic HLA-A2/CD20 kill primary follicular lymphoma and acute lymphoblastic leukemia cells
Int J Cancer, 130 (8), 1821-32
DOI 10.1002/ijc.26209, PubMed 21630262

Chrisanthar R, Knappskog S, Løkkevik E, Anker G, Ostenstad B, Lundgren S, Risberg T, Mjaaland I, Skjønsberg G, Aas T, Schlichting E, Fjösne HE, Nysted A, Lillehaug JR, Lønning PE (2011)
Predictive and prognostic impact of TP53 mutations and MDM2 promoter genotype in primary breast cancer patients treated with epirubicin or paclitaxel
PLoS One, 6 (4), e19249
DOI 10.1371/journal.pone.0019249, PubMed 21556366

Delabie J, Holte H, Vose JM, Ullrich F, Jaffe ES, Savage KJ, Connors JM, Rimsza L, Harris NL, Müller-Hermelink K, Rüdiger T, Coiffier B, Gascoyne RD, Berger F, Tobinai K, Au WY, Liang R, Montserrat E, Hochberg EP, Pileri S, Federico M, Nathwani B, Armitage JO, Weisenburger DD (2011)
Enteropathy-associated T-cell lymphoma: clinical and histological findings from the international peripheral T-cell lymphoma project
Blood, 118 (1), 148-55
DOI 10.1182/blood-2011-02-335216, PubMed 21566094

Figueira E, Lima A, Branco D, Quintino V, Rodrigues AM, Freitas R (2011)
Health concerns of consuming cockles (Cerastoderma edule L.) from a low contaminated coastal system
Environ Int, 37 (5), 965-72
DOI 10.1016/j.envint.2011.03.018, PubMed 21507485

Fløisand Y, Delabie J, Fosså A, Helseth E, Jacobsen EA, Rolke J, Tjønnfjord GE (2011)
Richter syndrome presenting as a solitary cerebellar tumor during first-line treatment for chronic lymphocytic leukemia
Leuk Lymphoma, 52 (10), 2007-9
DOI 10.3109/10428194.2011.580480, PubMed 21663503

Grotmol T, Bray F, Holte H, Haugen M, Kunz L, Tretli S, Aalen OO, Moger TA (2011)
Frailty modeling of the bimodal age-incidence of Hodgkin lymphoma in the Nordic countries
Cancer Epidemiol Biomarkers Prev, 20 (7), 1350-7
DOI 10.1158/1055-9965.EPI-10-1014, PubMed 21558495

Hadzidimitriou A, Agathangelidis A, Darzentas N, Murray F, Delfau-Larue MH, Pedersen LB, Lopez AN, Dagklis A, Rombout P, Beldjord K, Kolstad A, Dreyling MH, Anagnostopoulos A, Tsaftaris A, Mavragani-Tsipidou P, Rosenwald A, Ponzoni M, Groenen P, Ghia P, Sander B, Papadaki T, Campo E, Geisler C, Rosenquist R, Davi F et al. (2011)
Is there a role for antigen selection in mantle cell lymphoma? Immunogenetic support from a series of 807 cases
Blood, 118 (11), 3088-95
DOI 10.1182/blood-2011-03-343434, PubMed 21791422

Hagtvedt T, Aaløkken TM, Smith HJ, Graff BA, Holte H, Kolbenstvedt A (2011)
Enhancement characteristics of lymphomatous lymph nodes of the mediastinum
Acta Radiol, 52 (10), 1113-8
DOI 10.1258/ar.2011.110265, PubMed 22052959

Josefsen D, Forfang L, Dyrhaug M, Blystad AK, Stokke T, Smeland EB, Kvalheim G (2011)
Side population cells in highly enriched CD34-positive cells from peripheral blood progenitor cells identify an immature subtype of hematopoietic progenitor cells but do not predict time to engraftment in patients treated with high-dose therapy
Eur J Haematol, 87 (6), 494-502
DOI 10.1111/j.1600-0609.2011.01681.x, PubMed 21752097

Navalho M, Resende C, Rodrigues AM, Gaspar A, Fonseca JE, Canhão H, Campos J (2011)
Dynamic contrast-enhanced 3-T magnetic resonance imaging: a method for quantifying disease activity in early polyarthritis
Skeletal Radiol, 41 (1), 51-9
DOI 10.1007/s00256-011-1112-8, PubMed 21318271

Negaard HF, Sandset PM, Kolset SO, Svennevig K, Østenstad B, Iversen PO (2011)
Associations between regulators of extracellular matrix and hemostatic factors in hematologic neoplasias
Leuk Lymphoma, 52 (6), 1157-9
DOI 10.3109/10428194.2011.563886, PubMed 21463121

Polido-Pereira J, Rodrigues AM, Canhão H, Saraiva F, da Silva JA, Fonseca JE (2011)
Primary biliary cirrhosis in a rheumatoid arthritis patient treated with rituximab, a case-based review
Clin Rheumatol, 31 (2), 385-9
DOI 10.1007/s10067-011-1879-y, PubMed 22042492

Skaali T, Fosså SD, Andersson S, Cvancarova M, Langberg CW, Lehne G, Dahl AA (2011)
Self-reported cognitive problems in testicular cancer patients: relation to neuropsychological performance, fatigue, and psychological distress
J Psychosom Res, 70 (5), 403-10
DOI 10.1016/j.jpsychores.2010.12.004, PubMed 21511070

Torfoss D, Høiby EA, Holte H, Kvaløy S (2011)
The Norwegian experience with penicillin G plus an aminoglycoside as initial empiric therapy in febrile neutropenia; a review
Acta Oncol, 51 (4), 433-40
DOI 10.3109/0284186X.2011.633931, PubMed 22175253

Torfoss D, Sandstad B, Mollnes TE, Høiby EA, Holte H, Bjerner J, Bjøro T, Gaudernack G, Kvalheim G, Kvaløy S (2011)
The mild inflammatory response in febrile neutropenic lymphoma patients with low risk of complications is more pronounced in patients receiving tobramycin once daily compared with three times daily
Scand J Immunol, 74 (6), 632-9
DOI 10.1111/j.1365-3083.2011.02618.x, PubMed 21883353

Tsai HR, Gjesdal O, Wethal T, Haugaa KH, Fosså A, Fosså SD, Edvardsen T (2011)
Left ventricular function assessed by two-dimensional speckle tracking echocardiography in long-term survivors of Hodgkin's lymphoma treated by mediastinal radiotherapy with or without anthracycline therapy
Am J Cardiol, 107 (3), 472-7
DOI 10.1016/j.amjcard.2010.09.048, PubMed 21257017

Wahlin BE, Sundström C, Holte H, Hagberg H, Erlanson M, Nilsson-Ehle H, Lindén O, Nordström M, Ostenstad B, Geisler CH, Brown Pde N, Lehtinen T, Maisenhölder M, Tierens AM, Sander B, Christensson B, Kimby E (2011)
T cells in tumors and blood predict outcome in follicular lymphoma treated with rituximab
Clin Cancer Res, 17 (12), 4136-44
DOI 10.1158/1078-0432.CCR-11-0264, PubMed 21518780

Wahlin BE, Yri OE, Kimby E, Holte H, Delabie J, Smeland EB, Sundström C, Christensson B, Sander B (2011)
Clinical significance of the WHO grades of follicular lymphoma in a population-based cohort of 505 patients with long follow-up times
Br J Haematol, 156 (2), 225-33
DOI 10.1111/j.1365-2141.2011.08942.x, PubMed 22126847

Weisenburger DD, Savage KJ, Harris NL, Gascoyne RD, Jaffe ES, MacLennan KA, Rüdiger T, Pileri S, Nakamura S, Nathwani B, Campo E, Berger F, Coiffier B, Kim WS, Holte H, Federico M, Au WY, Tobinai K, Armitage JO, Vose JM, International Peripheral T-cell Lymphoma Project (2011)
Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project
Blood, 117 (12), 3402-8
DOI 10.1182/blood-2010-09-310342, PubMed 21270441

Yri OE, Torfoss D, Hungnes O, Tierens A, Waalen K, Nordøy T, Dudman S, Kilander A, Wader KF, Ostenstad B, Ekanger R, Meyer P, Kolstad A (2011)
Rituximab blocks protective serologic response to influenza A (H1N1) 2009 vaccination in lymphoma patients during or within 6 months after treatment
Blood, 118 (26), 6769-71
DOI 10.1182/blood-2011-08-372649, PubMed 22058114

Publications 2010

Brabrand S, Fosså SD, Cvancarova M, Lehne G (2010)
Androgen substitution with testosterone undecanoate in survivors of bilateral testicular cancer requires individually-adjusted injection intervals
BJU Int, 107 (7), 1080-7
DOI 10.1111/j.1464-410X.2010.09649.x, PubMed 20825398

Cascão R, Moura RA, Perpétuo I, Canhão H, Vieira-Sousa E, Mourão AF, Rodrigues AM, Polido-Pereira J, Queiroz MV, Rosário HS, Souto-Carneiro MM, Graca L, Fonseca JE (2010)
Identification of a cytokine network sustaining neutrophil and Th17 activation in untreated early rheumatoid arthritis
Arthritis Res Ther, 12 (5), R196
DOI 10.1186/ar3168, PubMed 20961415

Eide MB, Liestøl K, Lingjaerde OC, Hystad ME, Kresse SH, Meza-Zepeda L, Myklebost O, Trøen G, Aamot HV, Holte H, Smeland EB, Delabie J (2010)
Genomic alterations reveal potential for higher grade transformation in follicular lymphoma and confirm parallel evolution of tumor cell clones
Blood, 116 (9), 1489-97
DOI 10.1182/blood-2010-03-272278, PubMed 20505157

Hagtvedt T, Aaløkken TM, Smith HJ, Graff BA, Holte H, Kolbenstvedt A (2010)
Enhancement characteristics of lymphomatous lymph nodes of the neck
Acta Radiol, 51 (5), 555-62
DOI 10.3109/02841851003698198, PubMed 20429760

Kiserud CE, Loge JH, Fosså A, Holte H, Cvancarova M, Fosså SD (2010)
Mortality is persistently increased in Hodgkin's lymphoma survivors
Eur J Cancer, 46 (9), 1632-9
DOI 10.1016/j.ejca.2010.02.010, PubMed 20219350

Mauz-Körholz C, Hasenclever D, Dörffel W, Ruschke K, Pelz T, Voigt A, Stiefel M, Winkler M, Vilser C, Dieckmann K, Karlén J, Bergsträsser E, Fosså A, Mann G, Hummel M, Klapper W, Stein H, Vordermark D, Kluge R, Körholz D (2010)
Procarbazine-free OEPA-COPDAC chemotherapy in boys and standard OPPA-COPP in girls have comparable effectiveness in pediatric Hodgkin's lymphoma: the GPOH-HD-2002 study
J Clin Oncol, 28 (23), 3680-6
DOI 10.1200/JCO.2009.26.9381, PubMed 20625128

Moura RA, Cascão R, Perpétuo I, Canhão H, Vieira-Sousa E, Mourão AF, Rodrigues AM, Polido-Pereira J, Queiroz MV, Rosário HS, Souto-Carneiro MM, Graca L, Fonseca JE (2010)
Cytokine pattern in very early rheumatoid arthritis favours B-cell activation and survival
Rheumatology (Oxford), 50 (2), 278-82
DOI 10.1093/rheumatology/keq338, PubMed 21047805

Moura RA, Weinmann P, Pereira PA, Caetano-Lopes J, Canhão H, Sousa E, Mourão AF, Rodrigues AM, Queiroz MV, Souto-Carneiro MM, Graça L, Fonseca JE (2010)
Alterations on peripheral blood B-cell subpopulations in very early arthritis patients
Rheumatology (Oxford), 49 (6), 1082-92
DOI 10.1093/rheumatology/keq029, PubMed 20211867

Sampaio L, Rodrigues AM, Quintino V (2010)
Carbon and nitrogen stable isotopes in coastal benthic populations under multiple organic enrichment sources
Mar Pollut Bull, 60 (10), 1790-802
DOI 10.1016/j.marpolbul.2010.06.003, PubMed 20594560

Skaali T, Fosså SD, Andersson S, Cvancarova M, Langberg CW, Lehne G, Dahl AA (2010)
A prospective study of neuropsychological functioning in testicular cancer patients
Ann Oncol, 22 (5), 1062-1070
DOI 10.1093/annonc/mdq553, PubMed 21048038

Tauro S, Cochrane L, Lauritzsen GF, Baker L, Delabie J, Roberts C, Mahendra P, Holte H (2010)
Dose-intensified treatment of Burkitt lymphoma and B-cell lymphoma unclassifiable, (with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma) in young adults (<50 years): a comparison of two adapted BFM protocols
Am J Hematol, 85 (4), 261-3
DOI 10.1002/ajh.21648, PubMed 20201088

Tierens AM, Holte H, Warsame A, Ikonomou IM, Wang J, Chan WC, Delabie J (2010)
Low levels of monoclonal small B cells in the bone marrow of patients with diffuse large B-cell lymphoma of activated B-cell type but not of germinal center B-cell type
Haematologica, 95 (8), 1334-41
DOI 10.3324/haematol.2009.014100, PubMed 20145271

van Oers MH, Tönnissen E, Van Glabbeke M, Giurgea L, Jansen JH, Klasa R, Marcus RE, Wolf M, Kimby E, Vranovsky A, Holte H, Hagenbeek A, van der Reijden BA (2010)
BCL-2/IgH polymerase chain reaction status at the end of induction treatment is not predictive for progression-free survival in relapsed/resistant follicular lymphoma: results of a prospective randomized EORTC 20981 phase III intergroup study
J Clin Oncol, 28 (13), 2246-52
DOI 10.1200/JCO.2009.25.0852, PubMed 20368567

van Oers MH, Van Glabbeke M, Giurgea L, Klasa R, Marcus RE, Wolf M, Kimby E, van t Veer M, Vranovsky A, Holte H, Hagenbeek A (2010)
Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study
J Clin Oncol, 28 (17), 2853-8
DOI 10.1200/JCO.2009.26.5827, PubMed 20439641